Xanthines as Adenosine Receptor Antagonists

Christa Müller¹ and Kenneth A. Jacobson²

Christa Müller: christa.mueller@uni-bonn.de; Kenneth A. Jacobson: kajacobs@helix.nih.gov

¹PharmaCenter Bonn, Pharmaceutical Sciences Bonn (PSB), University of Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, An der Immenburg 4, D-53121 Bonn, Germany, Phone +49-228-73-2301, Fax +49-228-73-2567

²Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bldg. 8A, Rm. B1A-19, NIH, NIDDK, LBC, Bethesda, MD 20892, United States of America, Phone +1-301-496-9024, Fax +1-301-480-8422

Abstract

The natural plant alkaloids caffeine and theophylline were the first adenosine receptor (AR) antagonists described in the literature. They exhibit micromolar affinities and are non-selective. A large number of derivatives and analogs have subsequently been synthesized and evaluated as AR antagonists. Very potent antagonists have thus been developed with selectivity for each of the four AR subtypes.

Keywords

adenosine receptors; A₁ receptor antagonists; A_{2A} receptor antagonists; A_{2B} receptor antagonists; A₃ receptor antagonists; caffeine; deazaxanthines; molecular probes; paraxanthine; theobromine; theophylline; tricyclic xanthine derivatives; xanthines

1. Caffeine and theophylline - historical aspects and early structural modification

1.1. Naturally occurring xanthines

The earliest adenosine receptor (AR) antagonists identified were the naturally-occurring alkylxanthines, most notably among these being caffeine (1,3,7-trimethylxanthine, **1**) and theophylline (1,3-dimethylxanthine, **2**) (see Fig. 1) (Daly 1982; Fredholm 1999; Stefanovich 1989). Another simple natural xanthine, theobromine (**3**) was shown to have only weak activity as AR antagonist (Müller et al. 1993a). The major caffeine metabolites in humans, paraxanthine (**4**) and 1-methylxanthine (**5**) (Krämer and Testa 2008), the latter being also the major metabolite of theophylline, are similarly potent as caffeine and theophylline and may contribute their activity (Daly et al. 1986a; Müller et al. 1993b). These simple alkylxanthines are of micromolar affinity, at best, at the ARs, and variation of affinity between species has been documented (see table 1). This affinity range was later shown to apply generally to all human AR subtypes, A₁, A_{2A}, A_{2B} and A₃, but only to three of the AR subtypes of the rat (A₁, A_{2A}, and A_{2B}). At the rat A₃AR, the simple alkylxanthines were shown to have much higher K_i values of ~ 10⁻⁴ M or higher (Fredholm et al. 1994; van Galen et al. 1994).

1.1. Early modification of 8-unsubstituted xanthine derivatives

The first xanthine analogues with enhanced affinity at the ARs were modified from caffeine and theophylline (Daly 2000; Dlay 2007; Müller et al. 1993a; Fredholm et al. 2009). In the early 1980s, one particular type of modification of the xanthine structure proved to be especially useful in enhancing affinity: the elongation of the 1,3-dimethyl groups to propyl or larger alkyl groups (Bruns 1981; Ukena et al. 1986b). For example, substitution of the 1,3-dimethyl groups with 1,3-dipropyl groups in **16** increased affinity at the rat A₁AR by ~20-fold (table 1). Substitutions at the 1-, 3-, or 7-positions, particularly small hydrophobic groups, were generally much better tolerated in AR binding than substitution at the 9-position (Daly 1982; Müller et al. 1993a). Evaluation of a series of mono-substituted xanthines (**5–14**) showed that substitution at N1 was most important for all AR subtypes (Müller et al., 1993b). While a 1-propyl residue was best for A_{2B} and A₃ receptors, a 1-benzyl residue was optimal for the A₁ and A_{2A} AR subtypes (see table 1). 1-Propylxanthine (**6**) shows the highest affinity of the small, simple xanthine derivatives for the human A_{2B} receptor (K_i 360 nM) along with some selectivity (at least 7-fold vs. the other subtypes) (Kim et al. 2002), while 3-propylxanthine (enprofylline, **10**) is less potent (K_i human A_{2B} 4,730 nM), but even more selective (at least 14-fold).

3,7-Dimethyl-1-propargylxanthine (DMPX, **20**) was the first A₂-selective AR antagonist described in the literature (Ukena et al. 1986b; Seale et al. 1988). It is similarly potent at A_{2A} and A_{2B} receptors, but the degree of selectivity versus A₁ receptors is low (Jacobson et al. 1992a). A comparison with the 7-unmethylated derivative 3-methyl-1-propargylxanthine (**18**) indicated that a 7-methyl group led to a large decrease in A₁ affinity and thus increased selectivity for A_{2A} or A_{2B} (Müller et al. 1993b; Kim et al. 2002). The theophylline derivative doxofylline **15** bearing a 1,3-dioxolan-2-ylmethyl residue in the 7-position is virtually inactive at A₁ and A_{2A}AR and is believed to exert its antiasthmatic activity via inhibition of phosphodiesterases (Cirillo et al. 1988; Shukla et al. 2009).

The branched analogue IBMX **17** shows potency as a phosphodiesterase (PDE) inhibitor in the same concentration range as is required to block ARs (Ukena et al. 1993).

1,3-Dibutylxanthine-7-ribosides (**21,22**) were found to bind effectively at A₃ receptors indicating that the ribose group – as in adenosine – can act as a secondary anchor or recognition moiety in the receptor binding site (van Galen et al. 1994; Kim et al. 1994b; Park et al. 1998). This series of xanthine-7-ribosides also provided an early indication of modes of ligand binding at ARs, i.e. the overlay of receptor-bound positions of xanthine and adenine moieties. The 5'-uronamide modification of the CH₂OH group of the ribose moiety greatly enhanced A₃AR affinity as was shown for adenosine agonists, such that DBXRM was 143-fold selective (Kim et al. 1994b). DBXRM (**22**) was found to be a full agonist at the A₃AR, unlike other xanthine derivatives. It is proposed that the ribose moiety contains the essential structure and required flexibility to effect the conformational change of the receptor needed for activation (Gao et al. 2002).

1.2. Progression to xanthines with subtype selectivity

In addition to substitution of the 1,3-dimethyl groups with larger 1,3-dialkyl groups, a means of increasing affinity at the rat A₁AR was found to be the introduction of 8-aryl substituents (fig. 2 and table 2) (Bruns 1981; Daly et al. 1986b; Jacobson et al. 1988; Jacobson et al. 1992a; Müller et al. 1996). For example, placement of a phenyl group at the 8-position, generally increased A₁AR affinity by at least an order of magnitude (table 2). The first analogue having both 1,3-dialkyl and 8-phenyl modifications to be studied in detail was 1,3-diethyl-8-phenylxanthine (DPX, **25**), which displayed a K_i value of 44 nM at the rat A₁AR and was beginning to show selectivity for that subtype (Bruns et al. 1987a). [³H]DPX was

demonstrated as the first AR antagonist radioligand, but its hydrophobicity limited its use (Bruns et al. 1980). Homologation to the 1,3-propyl groups in the 8-aryl analogue **26** provided a desired boost in affinity, however, the unintended consequence of rapidly diminishing aqueous solubility made this series unable to be used in typical pharmacological studies (Ukena et al. 1986b; Bruns and Fergus 1989). The 8-*p*-hydroxyphenyl-substituted derivative **33** (NPC-205) was slightly more potent than **26** (Shamim et al. 1988). The low aqueous solubility, which is both a function of lipophilic groups present on the xanthine and the tendency of 8-aryl xanthine derivatives to form highly stable crystal lattices, resulted in low bioavailability of **26** and similar compounds (Müller et al. 1996; Frédérick et al. 2005).

Several approaches were taken to increase the water solubility. A sulfonate group was introduced at the *p*-position of the 8-phenyl ring, which greatly increased solubility (Daly et al. 1985; Shamim et al. 1989). However, this modification tended to decrease both affinity and selectivity, in comparison to the uncharged 8-phenyl analogues. Thus, SPT (**27**) and DPSPX (**28**), the latter of which is somewhat more potent, were both useful in pharmacological experiments where a blockade of all AR subtypes is required. It has to be kept in mind that these compounds do not block rat A₃ receptors but are active at other species like human and sheep (table 2). SPT (**27**) was shown not to penetrate into the brain due to its high polarity (Baumgold et al. 1992).

2. Adenosine A₁ receptor antagonists

2.1. 8-Aryl- and 8-arylalkyl-substituted xanthines

An alternative approach to the introduction of charged groups for increasing water solubility resulted in the synthesis of the 8-aryl derivatives in which the charged group was separated from the phenyl ring by a spacer group. Various substitutions of an 8-phenyl ring indicated that an electron-donating group provided a favorable AR affinity (Jacobson et al. 1985b; Shamim et al. 1988). Thus, a methoxy substituent was elaborated into a carboxymethoxy group resulting in carboxylic congener XCC **36** and amine congener 8-[4-[[[(2-aminoethyl)amino]carbonyl]methyl]oxy]phenyl]-1,3-dipropylxanthine (XAC, **30**) (fig. 2 and table 2) (Jacobson et al. 1985b; Jacobson et al. 1999). By placing the charged group at a distance from the 8-aryl ring, it was possible to maintain and even enhance the high affinity seen with neutral, but poorly soluble analogues. Thus, XAC was found to have a K_i value of 1.2 nM at the rat A₁AR and ~50-fold selectivity in comparison to the rat A₂AR. The initial measure of A₂AR affinity used in Jacobson et al. (1985b) was the inhibition of cyclic AMP accumulation in rat brain slices, which corresponds more closely to the A_{2B}AR, rather than the A_{2A}AR. However, subsequent tests at the rat A_{2A}AR confirmed that there was still a margin of selectivity of XAC in binding to the A₁AR in rat (Ukena et al. 1986c). The substitution of the 1,3-dipropyl groups of XAC with 1,3-diethyl increased affinity at the A_{2A}AR while decreasing it at the A₁AR (Jacobson et al. 1987a). The aqueous solubility of XAC was found to be 25 µM, which was an improvement over the uncharged 8-aryl derivatives. Therefore, XAC was suitable for use in pharmacological experiments as a general AR antagonist and was the first such antagonist to display moderate A₁AR selectivity at least in rat.

Given the promise of a relatively water-soluble and somewhat selective xanthine derivative, this amine-functionalized derivative of 1,3-dipropyl-8-phenylxanthine was specifically radiolabeled on the 1,3-dipropyl groups by catalytic reduction of a 1,3-diallyl precursor. The resulting [³H]XAC was useful as a radiotracer in binding experiments at rat cerebral cortical A₁ARs with a K_D value of ~ 1 nM, and was thus the first generally useful antagonist radioligand for study of this receptor (Jacobson et al. 1986a). [³H]XCC **36** was also introduced as a high affinity radioligand for the A₁AR (Jarvis et al. 1987).

Another rationale for the design of XAC with a primary amino group was the “functionalized congener approach” to drug design (Jacobson et al. 1986b; Jacobson 2009). By this approach, a chemically functionalized chain is incorporated at an insensitive site on the xanthine pharmacophore and can be extended to enable a conjugation strategy. Such high affinity conjugates are useful for AR characterization and can be coupled to radioactive or spectroscopic reporter groups without losing the ability to bind to the receptor (Jacobson et al. 1987b). XAC was also used as an immobilized high-affinity ligand for the purpose of affinity chromatography leading to the isolation of both A₁ and A_{2A} receptors and their purification to homogeneity (Olah et al. 1989; Weiss and Grisshammer 2002). While in XAC the polar, basic residue was connected to the 8-phenyl ring via ether and amide linkages, in another series sulphonamide-linked derivatives were investigated (**31,32**, fig. 2). Compound **31** and its congeners were potent A₁ antagonists, but showed only a moderate degree of selectivity (table 2) (Bruns et al. 1986; Bruns et al. 1987a).

Besides 8-phenylxanthine derivatives 8-benzyl- (**62**) and 8-phenylethyl-substituted xanthines (**59–61**) have also been investigated and optimized with respect to A₁ affinity (Peet et al. 1993). Among 8-(arylalkyl)-xanthine derivatives, 3-[2-(4-aminophenyl)ethyl]-8-benzyl-7-{2-ethyl(2-hydroxyethyl)amino}ethyl-1-propyl-3,7-dihydropurine-2,6-dione (L-97-1, **62**) is weaker in binding than typical 8-aryl xanthine probes, but is a water soluble A₁ AR antagonist bearing a basic substituent at N7 that has been proposed for the treatment of asthma (Obiefuna et al., 2005). 1,3-Dipropyl-8-phenylethyl-xanthine derivatives with a methyl (**59–60**) or ethyl (**61**) substituent at the α -carbon atom adjacent to the xanthine C8-position showed particularly high affinity and selectivity for A₁AR with a configurational preference for the (*R*)- over the (*S*)-enantiomer (Peet et al. 1993).

2.2. 8-Cycloalkylxanthines

The introduction of 8-cycloalkyl groups instead of 8-aryl groups proved to be beneficial for affinity at the A₁AR, and also allowed sufficient aqueous solubility for broad pharmacological application (fig. 3 and table 3). The 8-cycloalkylxanthine derivative that is most widely used as a pharmacological tool is DPCPX (**65**, also known as CPX), which is ~500-fold selective for rat A₁AR in comparison to the A_{2A}AR (Bruns et al. 1987a). Among the human ARs, the A₁AR selectivity is less than in the rat (table 3). The corresponding cyclohexyl analogue is similar in its pharmacological profile (Shamim et al. 1989). Curiously, DPCPX was in clinical trials for the treatment of cystic fibrosis through a non-AR related mechanism. It was found to act on the CFTR (cystic fibrosis-related chloride transporter) to enhance chloride in cells systems, an action that is unrelated to its AR antagonism (Cohen et al. 1997; Sorbera et al. 2000).

More bulky cycloalkyl substituents in the xanthine 8-position, such as 3-noradamantyl (e.g. rolofylline (KW3902, **69**) and **77**), (substituted) norbornyl (naxifylline (BG-9719, CVT124, **80**), and the lactone **81**), dicyclopropylmethyl (MPDX, **83**, and KF15372, **84**) and bicyclo[2.2.2]octyl (toponafylline (BG-9928, **82**)) yielded very potent and selective A₁ antagonists (fig. 3 and table 3).

The 2-thio analog of DPCPX (**65**), 2-thio-DPCPX (**66**) was similarly potent and selective as **65** showing that in the 2-position a hydrogen bond acceptor (like a keto group) was not required (Jacobson et al. 1989b)). Replacement of the 3-propyl residue in DPCPX by a phenyl (**73**), benzyl (**72**), or a chiral methylbenzyl residue (**70,71**) was well tolerated (Weyler et al. 2006). However, the affinity for the human A₃AR was increased by the lipophilic, aromatic residues, and the compounds lost A₁-selectivity vs. A₃. The introduction of polar hydroxy groups in the 3-position was well tolerated by the A₁, but not by the A₃AR leading to very potent and highly selective A₁ antagonists (**74,75,77–79**) (Weyler et al.

2006; Massip et al. 2006). In fact, 1-butyl-3-(3-hydroxypropyl)8-(3-noradamantyl)xanthine (PSB-36, **77**) is one of the most potent A₁ antagonists described to date showing K_i values of 0.124 nM (rat), and 700 nM (human), respectively. The hydroxylated DPCPX derivative **74** (PSB-16) was converted to its phosphoric acid ester disodium salt, yielding a highly water-soluble A₁ antagonist prodrug suitable for parenteral application without the need for detergents and organic solvents (Weyler et al. 2006).

Several other polar derivatives and analogs of DPCPX were developed in order to further improve water-solubility and bioavailability. Apaxifylline (**67**) with a keto group at C3 of the cyclopentyl ring was clinically evaluated as a memory-enhancing drug for the treatment of dementias (Schingnitz et al. 1991). An amino-substituted DPCPX derivative, midaxifylline (**68**) has also been investigated (Ceccarelli et al. 1995). A promising second-generation compound currently undergoing clinical trials for the treatment of chronic heart failure is toponafylline (**82**), which contains a carboxylate function (Doggrell, 2005). Rolofylline (**69**), an A₁ antagonist of the first generation, had shown promising results in a pilot phase III study in patients with acute heart failure, but in a recently published larger phase III study (PROTECT) it did not exhibit significant improvement over placebo (Slawsky et al. 2009). Further potential applications for A₁AR antagonists include hypertension and renal diseases due to their diuretic and kidney-protective effects. The feasibility of designing kidney-selective prodrugs of an A₁AR antagonist has been demonstrated (Barone et al. 1989). Yet other applications are cardiac arrhythmia, asthma and other respiratory disorders, and the prevention of organ damage, e.g. resulting from transplantation (Jacobson et al. 1992a; Müller et al. 1996; Müller 1997; Jacobson et al. 2006; Moro et al. 2006; Givertz 2009).

2.3. Species differences

Among the human ARs, the A₁AR affinity and selectivity (vs. A_{2A} and A_{2B}AR) of 8-cycloalkyl and 8-aryl derivatives is typically less than in the rat (see table 2 and 3). Several groups have studied the species dependence of the AR affinity of xanthine derivatives (see Ukena et al. 1986b; Klotz et al. 1991; Müller et al. 1993; Müller 1997; Kull et al. 1999; Fozard et al. 2003; Auchampach 2009). An early conclusion was that the affinity of typical 8-substituted analogues (both aryl and cycloalkyl) was greatest at the bovine A₁AR, intermediate at the rat A₁AR, and lowest at the porcine A₁AR. Later, it was found that the human A₁AR most closely resembled the porcine A₁AR, in that respect. At the A_{2A} and the A_{2B}AR the opposite is true although differences are moderate: 8-substituted xanthines, such as XAC and DPCPX, are more potent at the human receptor than at the rat ortholog. The largest species differences are observed for the A₃ receptor: 8-phenyl- and 8-cyclopentylxanthines are typically much more potent at the human than at the rat A₃ receptor (Linden 1994; Ji et al. 1994; Jacobson 1998; Müller 2001; Müller 2003).

2.4. Deaza- and azaxanthines

Analogues of xanthine derivatives, such as caffeine, theophylline, and 1,3-dialkyl-8-phenylxanthine have been synthesized which are lacking either the N7 (“7-deazaxanthines”) or the N9 nitrogen atom (“9-deazaxanthines”) in the imidazole partial structure (compounds **109–116**, fig. 5 and table 5). It was found that the nitrogen atom in the 9-position was not required for high receptor affinity, the 9-deazaxanthines being even slightly more potent at A₁AR in comparison with the corresponding xanthine derivatives (Grahner et al., 1994). To the contrary, 7-deazaxanthines were much less potent proving that the xanthines will bind as 7*H*-rather than 9*H*-tautomers to the receptors (Grahner et al., 1994). The addition of another nitrogen atom into the 8-position of xanthines was less successful: 8-azaxanthines (**123–126**, fig. 5 and table 5) showed only moderate affinity for the receptors (Franchetti et al. 1994).

which can be explained by the lacking of the N7-*H* atom that is required as a hydrogen bond donor for high-affinity binding.

2.5. Tricyclic xanthine derivatives

Several different types of tricyclic xanthine derivatives have been prepared and investigated (fig. 6 and table 6). Cycloalkyl-substituted dihydro-imidazo[2,1-*i*]purinones (**127,128**) showed high A₁ affinity and selectivity combined with improved water-solubility due to the presence of a basic nitrogen atom that can be protonated (Suzuki et al. 1992; Vu et al. 2006). A new class of heterotricyclic xanthine derivatives in which the 3-alkyl-substituent is tethered to the N9 atom – pyrimido[1,2,3-*cd*]purinediones (**151–153**) – was synthesized and investigated (fig. 6) (Weyler et al. 2006). Interestingly, the cyclopentyl-substituted derivative **151**, an analog of DPCPX, was only weakly active probably due to the lacking of the N7-H atom. In contrast, the 3-noradamantyl-substituted analogs (**152,153**) showed relatively high A₁ affinity. While propyl derivative **152** (PSB-63) was very selective versus the other AR subtypes, butyl derivative **153** was also quite potent at human A₃AR (table 6). Another novel tricyclic analog of DPCPX, the oxazolo[3,2-*a*]purinone derivative **154**, showed only weak affinity for AR (table 6) (Müller 1994). In a series of tricyclic pyrimido[2,1-*f*]purinediones the N,N-dipropyl-substituted derivative **139** (fig. 6) bearing a *m*-chlorobenzyl residue attached to the additional ring was a relatively potent A₁ antagonist with some selectivity (table 6) (Drabczynska et al. 2007a).

3. Adenosine A_{2A} receptor antagonists

A_{2A}AR selective antagonists of both xanthine and nonxanthine classes have been developed and some have entered clinical trials for Parkinson's disease, based on the opposing action of adenosine and dopamine in the striatal pathways in the brain (Richardson et al. 1997; Schapira et al. 2006; Schwarzschild et al. 2006; Müller et al. 2007; Baraldi et al. 2008). The cellular mechanisms of the motor and neuroprotective effects of A_{2A}AR antagonists have been explored (Yu et al. 2008). Recently, ameliorating effects of A_{2A} antagonists including xanthine derivatives on animal models of Alzheimer's disease and cognitive dysfunction have been reported (Dall'Igna et al. 2007; Cunha et al. 2008; Takahashi et al. 2008). Since the early 1990s, there has been a major medicinal chemical effort to increase the A_{2A}AR selectivity of simple xanthines by structural modification.

Prior to the synthesis of truly A_{2A}AR selective antagonists, certain high affinity xanthines were used in a nonselective fashion as probes of the A_{2A}AR. For example, [³H]XAC (**30**) was useful as a radiotracer in binding experiments at the A_{2A}AR in human platelets and was therefore the first antagonist radioligand with high affinity at the A_{2A}AR (Ukena et al. 1986a). PD115,199 **32** was prepared in tritiated form and shown to bind with high affinity to the rat A_{2A}AR (Bruns et al. 1987b).

The first "selective" A_{2A} receptor antagonist described in the literature was the caffeine analog 3,7-dimethyl-1-propargylxanthine (DMPX, **20**, fig. 1 and table 1) (Ukena et al. 1986b). Like caffeine, the compound possesses low A_{2A} receptor affinity and moderate selectivity versus A₁ receptors. Nevertheless, this compound has been widely used in *in vivo* studies because of its good water solubility and bioavailability (Seale et al. 1988; Thorsell et al. 2007). Later on it was found that DMPX is equally potent at A_{2B} as at A_{2A} receptors. The species dependence of affinity at the A_{2A} receptor of 1,3,7- and 1,3,8-trisubstituted xanthines has been reported (Stone et al. 1988).

An early example of a caffeine analogue that displayed selectivity for the A_{2A} receptor was 8-trifluoromethylcaffeine, but the affinity was still low with a K_i value in binding at the rat A_{2A}AR of 29 µM (Jacobson et al. 1993b). This effect of the 8-trifluoromethyl group was not

observed in the corresponding (inactive) theophylline derivative. A 8-(*trans*-2-carboxyvinyl) derivative of caffeine also proved to be similarly selective for the A_{2A} receptor.

3.1. 8-Styrylxanthines

The observation that N7-methylation in 8-substituted xanthine derivatives was better tolerated by the A_{2A} than the A₁ receptor (Shamim et al. 1989), and that the 8-substituent had to be coplanar for achieving high A_{2A} receptor affinity (Erickson et al. 1991) led to the first highly potent and selective A_{2A} receptor antagonists: the 1,3,7-alkyl-substituted 8-styrylxanthine derivatives **87–95** and **99** (table 4).

A small alkyl group at N1 (methyl, ethyl, propyl, propargyl) proved to be optimal for high A₁ affinity and selectivity, while methylation is required in the 7-position (Jacobson et al. 1993a; Nonaka et al. 1994a; Shimada et al. 1997; Müller et al. 1998a; Müller et al. 2000; Kase 2003). The 8-styryl residue has to be (*E*)-configured, and *meta*-chloro or –methoxy substitution improved affinity and selectivity. The *m*-position of the 8-styryl ring can be substituted with elongated chains with retention of A_{2A} receptor selectivity and enhancement of water solubility (Jacobson et al. 1993a). The phenyl ring in the 8-styryl residue can be substituted by heterocyclic rings, such as a 3-thienyl ring (**102**) (Del Giudice et al. 1996).

The most common substituents at N3 in A_{2A} receptor-selective xanthine derivatives have been small alkyl residues, such as methyl, propyl, and 3-hydroxypropyl (reviewed Müller 2000; Cacciari et al. 2003; Vu 2005; Yuzlenko et al. 2006; Müller et al. 2007; Cristalli et al. 2007; Cristalli et al. 2009). Recently, the development of a new synthetic approach allowed the preparation of a series of xanthine derivatives with more variations in the 3-position (Massip et al. 2006). It was found that the A_{2A} receptor tolerated bulky, functionalized substituents in the 3-position. For instance, N3-phenoxypropyl-substituted 8-(methoxystyryl)xanthine derivatives (e.g. **103**) are potent and selective A_{2A} antagonists (Massip et al. 2006).

Some of the best A_{2A} antagonists were istradefylline (KW6002, **87**), *m*-chlorostyrylcaffeine (CSC, **89**), *m*-bromostyryl-DMPX (**93**), and MSX-2 (**99**). (*E*)-8-(3-chlorostyryl)caffeine (**89**) is not only a potent A_{2A} antagonist (K_i rA_{2A} 54 nM), but in addition, it has been reported to be a potent inhibitor of monoamineoxidase B (baboon MAO-B, K_i 80.6 nM), an enzyme which metabolizes dopamine (van den Berg et al. 2007; Petzer et al. 2009). This activity may contribute to the potency of CSC in in vivo studies, e.g. in animal models of Parkinson's disease. All other styrylxanthine derivatives investigated so far, including 8-styrylcaffeine (**88**) and istradefylline (**87**), are considerably less potent as MAO-B inhibitors than CSC. Recently, a chain-extended homolog of CSC, 8-(*m*-chlorophenylbutadienyl)caffeine (**108**) has been described to show similar dual activity as A_{2A} antagonist and MAO-B inhibitor (Pretorius et al. 2008).

Istradefylline (KW-6002, **87**) has been intensively studied in vitro and in a number of animal models. Until recently (Fernandez et al. 2010), it was in Phase IIIb clinical trials for Parkinson's disease. In phase II clinical trials istradefylline reduced motoric dysfunction without producing dyskinesias (reviewed by Knutsen et al. 2001). An ¹¹C-labelled version of istradefylline has been prepared and used for positron emission tomography (PET) studies in healthy human brain (Hirani et al. 2001).

A major drawback of styrylxanthine derivatives, however, is their high lipophilicity and low water-solubility. Introduction of a polar sulfonate group into 8-styryl-DMPX resulting in compound **98** led to an almost 10-fold reduction in A_{2A} affinity, but increased water-solubility (Müller et al. 1998b). A more successful approach has been the preparation of

water-soluble prodrugs, particularly of the 3-(3-hydroxypropyl)-substituted 1-propargyl-8-styrylxanthine derivative MSX-2 (**99**) (Müller 2009). MSX-3 (**100**) is a water-soluble phosphate prodrug of MSX-2, which is cleaved *in vivo* by ubiquitous phosphatases to release the A_{2A} receptor antagonist MSX-2 (Sauer et al. 2000). MSX-3 has proven useful for animal studies and is widely used for studying the *in vivo* effects of A_{2A} antagonists (Hauber et al. 1998; Strömberg et al. 2000; Hauber et al. 2001; Ferré et al. 2001; Nagel et al. 2003; Blum et al. 2003; Schindler et al. 2004; Schindler et al. 2005; Antoniou et al. 2005; Karcz-Kubich et al. 2003a; Karcz-Kubicha et al. 2003b; Filip et al. 2006; Fuxe et al. 2007; Ishiwari et al. 2007; Farrar et al. 2007; Carriba et al. 2007; Salamone et al. 2008; Marcellino et al. 2008; Ferré et al. 2008; Mott et al. 2009; Worden et al. 2009). Due to its very high water-solubility at physiologic pH of 7.4 (9 mg/mL) it can be directly injected into specific brain areas, but is also an effective A_{2A} antagonist after systemic application. Recently, an amino acid ester prodrug of MSX-2, MSX-4 (**101**) has been synthesized, which was found to be well soluble in water, highly stable in artificial gastric fluid, but readily cleaved by esterases and may be a suitable prodrug for peroral administration (Vollmann et al. 2008).

Care has to be taken when using the (*E*)-configured styrylxanthines since they easily undergo light-induced isomerization in dilute solutions yielding mixtures of (*E*)- and (*Z*)-isomers, the (*Z*)-isomers being only weakly active or inactive (Nonaka et al. 1993; Müller et al. 1998b). This isomerisation does not occur in concentrated solution, e.g. during synthesis of the compounds, or when the compounds are applied as solid dosage forms. However, styrylxanthines can also undergo light-induced dimerization ([2+2]-cycloaddition reaction) in the solid state, and therefore have to be rigorously stored under exclusion of light (Hockemeyer et al. 2004).

3.2. Configurationally stable analogs of 8-styrylxanthines

To overcome the problem of the photoisomerization, the styryl moiety has been replaced with different more stable bioisosteric groups (e.g. replacement of the double bond for a cyclopropyl ring in **104**, a 2-naphthyl residue in **105**, a triple bond in **107**) (Müller et al. 1997c), or a tricyclic constrained structure (**133–143**) (Kiec-Kononowicz et al. 2001; Drabczynska et al. 2003; Fhidi et al. 2003; Drabczynska et al. 2004; Drabczynska et al. 2006; Drabczynska et al. 2007). In most cases a significant loss of affinity was observed by such modifications. The most promising compounds were the pyrimido[2,1-*f*]purinedione derivative **141** (K_i hA_{2A} 630 nM, rA_{2A} 230 nM) and 8-phenylethynyl-DMPX (**107**, K_i A_{2A} 314 nM, rA_{2A} 300 nM), both endowed with high selectivity. The latter class of compounds has been optimized towards increased A_{2A} affinity and the obtained highly potent and selective A_{2A} antagonists have been described in a recent patent (Müller et al. 2008). Furthermore, a substitution of the ethenyl group with a diazo structure has been performed. The obtained compounds retained selectivity but showed only moderate affinity (Müller et al. 1997b).

3.3. A_{2A}-selective radiolabelled xanthine derivatives

The tritiated derivative of the 8-styrylxanthine KF17837S (the equilibrium mixture of (*E*)- and (*Z*)- KF17837 isomers) was shown to bind to rat striatal membranes in a saturable and reversible way, with K_D values at low nanomolar concentration (Nonaka et al. 1994b). Another A_{2A} antagonist radioligand was prepared, [³H]3-(3-hydroxypropyl)-7-methyl-8-(*m*-methoxystyryl)-1-propargylxanthine ([³H]MSX-2). This molecule showed high affinity (K_D = 8.0 nM) for rat and human A_{2A} AR, with saturable and reversible binding, and also a selectivity of at least two orders of magnitude versus all other AR subtypes (Müller et al. 2000).

3.4. Heterocyclic compounds related to xanthines

A tricyclic styryl-substituted imidazo[2,1-*i*]purin-5-one derivative (**132**, fig. 6 and table 6) showed enhanced water-solubility but reduced A_{2A}R affinity and moderate selectivity (Müller et al. 2002a).

4. Adenosine A_{2B} receptor antagonists

4.1. Aryl-substituted 1,3-dialkylxanthines

From the initial studies of Daly and coworkers using cAMP studies in the brain slice, it was recognized that 1,3,7- and 1,3,8-trisubstituted xanthines have considerable affinity at the A_{2B}AR. Also, the simple xanthine enprofylline **10** was discovered to have slight selectivity for the A_{2B}AR, which was proposed to be responsible for its antiasthmatic action in the clinic (Stefanovich 1989; Daly 2000; Daly 2007). Screening efforts by Bruns (1981) followed by more detailed studies by Müller, Daly and Jacobson showed that 1-monosubstituted xanthine derivatives, such as 1-propylxanthine (**6**) and 1-butylxanthine (**7**) were about 10-fold more potent than enprofylline at A_{2B}AR and equally selective (Müller et al. 1993b; Kim et al. 2002).

In fact, the unintended interaction at the A_{2B}AR of widely used xanthine antagonists of the ARs has proven to be a complication in pharmacological studies.

Many known xanthines were screened at the A_{2B}AR to identify leads for the design of novel A_{2B}AR antagonists. The first successful efforts to enhance the activity of 1,3,8-trisubstituted xanthines at the A_{2B}AR by Jacobson and colleagues resulted in one compound of intermediate selectivity at the human, but not rat A_{2B}AR, MRS1595 (**41**), which is a hydrazide derivative of XCC (fig. 2 and table 2) (Kim et al. 2000). Then, further probing of SAR culminated in the introduction of MRS1754 (**37**), which was the first selective A_{2B}AR antagonist with nanomolar affinity at the human receptor (Kim et al. 2000). The degree of selectivity for the human A_{2B}AR was >120 fold, but selectivity for the rat A_{2B}AR was considerably less (fig. 2 and table 2). Thus, it remained a challenge to design a rat A_{2B}AR-selective xanthine antagonist. Another drawback in the series of anilide derivatives of XCC is the low aqueous solubility, which is partly remedied in related antagonists such as MRS1706 (**38**). Nevertheless, [³H]MRS1754 has found application as a useful radioligand of the A_{2B}AR (Ji et al. 2001). Structurally related 8-phenylxanthine derivatives include CVT-5440 (**40**), in which additional aromatic rings were attached by an ether linkage, and **42** with a modified 3-substituent (3-methoxypropyl), have been developed as potent and selective A_{2B} antagonists (Kim et al. 2000; Nieto et al. 2009). Newer derivatives in this series, which have two pyridine rings linked by an amide group, include the highly selective A_{2B}AR antagonists ATL-802 (**57**) and ATL-852 (**58**). [³H]ATL-852 has been reported as a high affinity radioligand at this receptor (Cagnina et al. 2009).

8-Pyrazolyl-substituted xanthines that have been developed as selective human A_{2B}AR antagonists include MRE-2029-F20 (**56**), which was also reported as a high affinity radioligand (Baraldi et al. 2004). A different series of isomeric 8-pyrazolyl-xanthines yielded the highly potent A_{2B} antagonists **53–55** (CVT-6694, CVT-7124 and CVT-6883) (Kalla et al. 2008; Elzein et al. 2008; Kalla et al. 2009). High selectivity at human receptors has been reported for all of these pyrazolylxanthines, but no data for rodent receptors has been reported. CVT-6883 (**55**) is a promising candidate for the treatment of diabetes or asthma and has entered phase I clinical trials. Pain treatment is another potential area under consideration for A_{2B}AR antagonists (Abo-Salem et al. 2004; Akkari et al. 2006; Bilkei-Gorzo et al. 2008; Michael et al. 2010).

4.2. 1,8-Disubstituted xanthines

The observation that 1-monosubstituted and 1,8-disubstituted xanthine derivatives showed high affinity and increased selectivity for A_{2B}AR led to the development of a series of 1-alkyl-8-phenylxanthine derivatives (**43–52**) (Hayallah et al. 2002; Yan et al. 2004; Yan et al. 2006; Borrmann et al. 2009). These compounds also appeared to show reduced affinity at the rat A₁ receptor and therefore increased A_{2B} selectivity in rat. 1-Propyl-8-*p*-sulfophenylxanthine (PSB-1115, **43**) was developed as a water-soluble A_{2B} antagonist, useful as a pharmacological tool for in vivo studies (Müller et al. 1993b; Kirfel et al. 1997; Abo-Salem et al. 2004; Bilkei-Gorzo et al. 2008). 1-Butyl-8-(*p*-carboxyphenyl)xanthine (PSB-53, **45**) showed similar affinity and selectivity. The 1-propargyl-8-*p*-bromophenylxanthine (PSB-50, **44**) was more potent, but somewhat less selective and much less water-soluble. The 8-phenylxanthine derivatives PSB-55 (**46**), a benzylpiperazine derivative, and PSB-298 (**47**), a hydroxyethylamide, were synthesized to obtain more polar compounds with high A_{2B} affinity. PSB-298 was obtained in tritiated form and was found to have a low degree of non-specific binding (Bertarelli et al. 2006). However, its affinity and selectivity was not satisfactory.

Starting from the sulfonate PSB-1115 (**43**), sulfonic acid esters (e.g. **48**) and sulphonamides (e.g. **49–52**) were obtained (Yan et al. 2004; Yan et al. 2006). Compound **48** can be envisaged as a lipophilic prodrug of the highly polar sulfonate **43**, which may show peroral bioavailability and release of **43** after absorption (Yan et al. 2004). However, **48** has high A_{2B} affinity itself and is therefore a co-drug rather than a prodrug, although without selectivity versus A₁AR (fig. 2 and table 2). The most potent and selective A_{2B} antagonists described to date are the sulphonamide derivatives **50–52**, whose development was based on PSB-601 (**49**) an already very potent and selective A_{2B} antagonist (K_i 3.6 nM). Compounds **50–52** show subnanomolar affinity for A_{2B} receptors and very high selectivity in humans and in rodents. [³H]PSB-603 was prepared as a selective, high-affinity A_{2B} antagonist radioligand with K_d values of 0.403 nM at human and 0.351 nM at mouse A_{2B}AR (Borrmann et al. 2009).

4.3. 9-Deazaxanthines

Several series of 9-deazaxanthine derivatives (**115**, **117–121**) were developed as A_{2B} antagonists, which were structurally related to the 8-phenylxanthine derivatives described above (fig. 5 and table 5). A number of compounds with low nanomolar affinity were obtained, and some were selective for the human A_{2B} receptor (Carotti et al. 2006; Esteve et al. 2006; Stefanachi et al. 2008).

4.4. 8-Furylmethyl-substituted xanthines

8-(2-Furyl)methyl-substituted xanthine derivatives, e.g. **63**, have been developed as A_{2B} antagonists (fig. 2 and table 2). Some of them showed high A_{2B} affinity but only moderate selectivity (Balo et al. 2009).

5. Adenosine A₃ receptor antagonists

In the search for A₃AR antagonists, alkylxanthines were initially rejected as a suitable lead in favor of nonxanthine chemically diverse heterocycles, because of the exceptionally low affinity of alkylxanthines at the rat A₃AR. For example, the classical adenosine antagonists caffeine and theophylline have K_i values of >100 μM at the rat A₃AR (table 1). Initial SAR studies at the rat A₃AR were conducted using multiply substituted xanthines, many of which retained selectivity for the A₃AR (van Galen et al. 1994). Only slight A₃AR selectivity was observed for analogues containing 8-alkyl and 2-thio substitutions (Kim et al. 1994b). However, when other species orthologues of the A₃AR were cloned and studied

pharmacologically, such as sheep, and human A₃AR, many xanthines were found to display good affinity for those A₃ receptors (Linden 1994). Thus, attention returned to the xanthines as a source for A₃AR antagonist leads.

One of the earliest approaches to enhancing the affinity of xanthines at the A₃AR was to attach a ribose group at the 7-position (**21,22**). The 5'-uronamide derivative *N*-methyl-1,3-dibutylxanthine-7-β-D-ribofuronamide (DBXRM, **22**) is 140-fold selective for the A₃AR, but the presence of the uronamide function increases the efficacy such that it is an agonist at this receptor (van Galen et al. 1994; Kim et al. 1994b; Bridson et al. 1998).

5.1. 8-Aryl-substituted xanthine derivatives

8-Phenylxanthine derivatives bearing a carboxylate group attached to the phenyl ring via an ethylene (**35**) or an oxymethylene spacer (**34**) were initially found to be potent antagonists at the human A₃AR, but both compounds are also very potent A₁ and A_{2B} antagonists (fig. 2 and table 2). [¹²⁵I]-ABOPX (BW-A522, **34**) has been used as a radioligand for labelling the A₁AR as well as human A₃ and human A_{2B}ARs (Patel et al. 1988; Salvatore et al. 1993; Linden et al. 1999). The corresponding *p*-azido derivative was previously used for photoaffinity labeling of the A₁AR. The xanthine derivative **34** is characterized by a *p*-amino-*m*-iodobenzyl residue at N3 of the xanthine core (fig. 2) and is therefore quite lipophilic. As observed for other xanthine antagonists, **34** is much less potent (65-fold) at rat as compared to human A₃ receptors.

5.2. Tricyclic xanthine and deazaxanthine derivatives

Cyclized derivatives of xanthines, such as (8*R*)-8-ethyl-4-methyl-2-phenyl-4,5,7,8-tetrahydro-1*H*-imidazo[2,1-*i*]purin-5-one (PSB-11, **130**), its trichloro-phenyl-substituted derivative PSB-10 (**129**), and the 8-unsubstituted 8-bromophenyl derivative **131** are very potent A₃-selective antagonists (fig. 6 and table 6) (Müller et al. 2002a; Saki et al. 2002; Ozola et al. 2003). PSB-11 (K_D 4.9 nM) was prepared as a radioligand by catalytic hydrogenation from the polychlorinated precursor PSB-10 (Müller et al. 2002b; Burbiel et al. 2003). Due to its increased polarity and solubility in comparison to xanthines [³H]PSB-11 shows only low non-specific binding. Further tricyclic xanthine derivatives, in which an additional ring was attached to the imidazole rather than the pyrimidine ring of the xanthine core structure (pyrido-, imidazo-, pyrrolo- and triazolo-purinediones, **144–150**), were developed as A₃-selective antagonists (Priego et al. 2002; Baraldi et al. 2005; Pastorin et al. 2005; Priego et al. 2008). An aromatic residue (mostly benzyl) attached to the N3 (xanthine numbering) increases A₃ affinity in xanthine derivatives including the tricyclic ones.

Besides tricyclic xanthine derivatives, tricyclic deazaxanthines have also been obtained (Ishiyama et al. 2009). Compound **122** (fig. 5 and table 5) was one of the most potent and selective compounds in this series.

6. Xanthine derivatives used as molecular probes

6.1. Irreversible ligand probes

The amine congener XAC (**30**) was coupled to a variety of bifunctional crosslinking reagents to form products containing a single chemically reactive group (fig. 7 and table 7). For example, 1,3- and 1,4-phenylene diisothiocyanates were conjugated to XAC to form the A₁ AR-selective antagonists *m*-DITC-XAC **164** and *p*-DITC-XAC **165**, which were demonstrated to bind irreversibly at submicromolar concentrations to the A₁AR to act as covalent affinity labels. Similarly, prosthetic reagents designed for radiolabeling and photoaffinity labeling could be coupled to XAC and similar amine congeners (Stiles et al.

1988; Jacobson et al. 1989a). The conjugate with the *p*-aminophenylacetyl moiety was readily iodinated to form the radioligand **172**, which could then be converted to the photoactivatable *p*-azide (Stiles and Jacobson 1987). This azide then served to crosslink a radiolabeled AR antagonist suitable to the A₁AR protein, which could be visualized by gel electrophoresis. The sulfonyl fluoride group present in **158** was also means of crosslinking a xanthine derivative to the A₁AR (Scammels et al. 1994; van Muijlswijk-Koezen et al. 2001).

6.2. Spectroscopic probes: spin labeled and fluorescent probes

Other types of reporter groups could be similarly incorporated into xanthine functionalized congeners with retention of moderate AR affinity, for example, chelating groups capable of complexing radioactive metal ions; spin labels for electron spin resonance (ESR) spectroscopy, e.g., **167**; a perfluorinated acyl prosthetic group, as in **170**, intended for use in fluorine-NMR spectroscopy, and fluorescent dyes, e.g., **173** and **174** (Jacobson et al. 1987b). The fluorescent conjugate **174** of XAC and BODIPY (6-(((4,4-difluoro-5-(2-thienyl)-4-bora-3a,4a-diaza-s-indacene-3-yl)styryloxy)acetic acid), with an intermediate ϵ -aminocaproyl spacer, has proven useful in fluorescence correlation spectroscopy to characterize ligand complexes of the A₁AR (Briddon et al. 2004).

Spin-labeled probes that retained high A₁ affinity were obtained by inserting the spin-label into the molecule as part of the pharmacophore. The most potent and A₁-selective compounds were the DPCPX analogs **155** (replacement of the 3-substituent by a spin label) and **156** (substitution of the cyclopentyl ring by a structurally related spin label). Both compounds showed affinity for A₁AR in the low nanomolar range combined with high selectivity versus the other receptor subtypes (Ilas et al. 2005). The 1-propyl-8-phenyl derivative **157**, in which the spin label was integrated into the 8-substituent, showed good affinity for A₁ as well as A_{2B} receptors (fig. 7 and table 7).

6.3. Specialized radioligand probes based on conjugation

Trifunctional probes derived from XAC were synthesized for the purpose of crosslinking to both a reporter group and the receptor (Boring et al. 1991). By this means, the xanthine would deliver a radioactive or spectroscopic prosthetic group to the receptor, to which it would react irreversibly by virtue of an electrophilic group such as an isothiocyanate. This approach was illustrated with a series of analogues of *m*-DITC-XAC containing a third substituent in the phenyl isothiocyanate ring. For example, in **166** the third substituent contained a 3-(4-hydroxy-phenyl)propionate moiety for radioiodination (Jacobson et al. 1992b). This antagonist derivative effectively radiolabeled the bovine A₁ AR in a covalent manner. Similar trifunctional xanthine probes for covalent labeling of ARs that furthermore contained a cleavable disulfide linkage within the chain linked to the xanthine moiety were reported (Jacobson et al. 1995). The intended strategy was to be able to remove the label after isolation of the modified receptor in order to regenerate the binding ability of the receptor.

6.4. Xanthine radioligand probes for positron emission tomography

There is a need for the development of imaging agents based on high affinity ligands for ARs. For example, ligands for *in vivo* positron emission tomographic (PET) imaging of A₁, A_{2A}, and A₃ ARs have been developed. The high affinity A₁AR antagonist DPCPX gave rise to the high affinity analogue in which a terminal hydrogen of the 3-propyl group has been substituted with radiofluorine: [¹⁸F]CPFPX (8-cyclopentyl-1-propyl-3-(3-fluoropropyl)-xanthine, **159**), similar in structure to DPCPX). This tracer is being developed for PET imaging of the A₁AR in the brain (Holschbach et al. 2002; Bauer et al. 2009).

PET ligands for the A_{2A} AR in the 8-styrylxanthine series that are structurally related to KW6002, have been developed: for example, [7-methyl-¹¹C]-(E)-8-(3,4,5-trimethoxystyryl)-1,3,7-trimethylxanthine ([¹¹C]TMSX) (Ishiwata et al. 2000a). This compound was alternately named [¹¹C]KF18446 ([7-methyl-¹¹C]-(E)-8-(3,4,5-trimethoxystyryl)-1,3,7-trimethylxanthine, (Ishiwata et al. 2000b; Ishiwata et al. 2002; Ishiwata et al. 2003a; Ishiwata et al. 2003b). Ex vivo autoradiography for this molecule showed a high striatal uptake and a high uptake ratio of the striatum in comparison to other brain regions; [¹¹C]KF18446 was therefore proposed as a suitable radioligand for mapping A_{2A}AR of the brain by PET (Mishina et al. 2007). In 2001 the synthesis and the testing of the 8-styrylxanthine derivative [¹¹C]KW-6002 as a PET ligand was reported. This molecule showed high retention in the striatum but it bound also to extra-striatal regions, so its potential as a PET ligand appeared to require further investigation (Hirani et al. 2001; Brooks et al. 2008).

In an earlier study, ¹¹C-labeled (E)-KF17837 was synthesised and tested, and it was proposed as a potential positron emission tomography (PET) radioligand for mapping the A_{2A}AR in the heart and the brain (Ishiwata et al. 1996; Ishiwata et al. 1997). Further studies on radiolabeled xanthine derivatives as A_{2A}AR radioligands were carried out by preparing and testing an ¹¹C-labeled selective antagonist, (E)-8-(3-chlorostyryl)-1,3-dimethyl-7-[¹¹C]methylxanthine [¹¹C]CSC). This molecule was shown to accumulate in the striatum, and PET studies on rabbits showed a fast brain uptake of [¹¹C]CSC, reaching a maximum in less than 2 min (Marian et al. 1999). Few years later, iodinated and brominated styrylxanthine derivatives labeled with ¹¹C were tested as *in vivo* probes (Ishiwata et al. 2000c). [7-Methyl-¹¹C]-(E)-3,7-dimethyl-8-(3-iodostyryl)-1-propargylxanthine ([¹¹C]IS-DMPX) and [7-methyl-¹¹C]-(E)-8-(3-bromostyryl)-3,7-dimethyl-1-propargylxanthine ([¹¹C]BS-DMPX) showed K_i affinities of 8.9 and 7.7 nM respectively, and high A_{2A}/A₁ selectivity values. Unfortunately, biological studies proved that the two ligands were only slightly concentrated in the striatum, and that they were not suitable as *in vivo* ligands because of low selectivity for the striatal A_{2A} receptors and a high nonspecific binding (Ishiwata et al. 2000c).

6.5. Conjugated ligand probes and bivalent ligands

Three biotin conjugates **161–163** of 1,3-dipropyl-8-phenylxanthine (fig 7) were reported as being able to bind competitively to the rat A₁ AR, but in the case of **161** and **162** only in the absence of avidin. This was in contrast to similar conjugates of functionalized nucleoside agonists, which more readily bound simultaneously to both avidin and the A₁ AR. Results were interpreted in terms of the possible reorientation of the ligands at the receptor binding site (Jacobson et al. 1985a; Jacobson 1990).

Two different pharmacophores, one being a xanthine AR antagonist, have been tethered with the intention to create a dual selectivity in a single functional unit. For example, XAC was coupled covalently through an L-Lys linker to a segment derived from the neurotransmitter peptide substance P (SP) to form a binary drug **169** (Jacobson et al. 1987c). The Lys linker served to increase aqueous solubility and to preserve A₁ AR by virtue of a free amino group in the spacer chain. Thus, conjugate **169** bound to the rat A₁ receptor with a K_i value of 35 nM and to the NK1 (neurokinin type 1) receptor with a K_i value of 300 nM. Similarly, XAC was coupled to functionalized agonist ligands for opioid receptors, e.g., **175**, and for D2 dopamine receptors, e.g., **176** (fig. 7 and table 7) (Jacobson 2009; Soriano et al. 2009). Each of these conjugates bound effectively to both relevant receptors.

7. Conclusions

The pharmacological activity of the natural xanthines currently used in therapy, namely theophylline (as an antiasthmatic) and caffeine (as CNS stimulant, for the treatment of apnoea in newborn babies, and as analgesic in combination therapy e.g. for the treatment of headaches) is mainly mediated by a (non-selective) inhibition of AR subtypes. AR subtype-selective xanthine derivatives with high potency have been developed and are evaluated in animal models and clinical trials.

Abbreviations

AR(s)	Adenosine receptor(s)
c	calf or cow
d	dog
CHO	Chinese hamster ovary
gp	guinea pig
h	human
m	mouse
MAO	monoaminoxidase
MAO-B	monoaminoxidase type B
mk	monkey
nd	not determined
p	pig
r	rat
rb	rabbit
s	sheep
X	xanthine(s)

References

- Abo-Salem OM, Hayallah AM, Bilkei-Gorzo A, Filipek B, Zimmer A, Müller CE. Antinociceptive effects of novel A_{2B} adenosine receptor antagonists. *J Pharmacol Exp Ther*. 2004; 308:358–366. [PubMed: 14563788]
- Alexander SP, Cooper J, Shine J, Hill SJ. Characterization of the human brain putative A_{2B} adenosine receptor expressed in Chinese hamster ovary (CHO.A2B4) cells. *Br J Pharmacol*. 1996; 119:1286–1290. [PubMed: 8937736]
- Antoniou K, Daifoti-Papadopoulou Z, Hyphantis T, Papathanasiou G, Bekris E, Marselos M, Panlilio L, Müller CE, Goldberg SR, Ferré S. A detailed behavioural analysis of the acute motor effects of caffeine in the rat: involvement of adenosine A₁ and A_{2A} receptors. *Psychopharmacology*. 2005; 183:154–162. [PubMed: 16205915]
- Akkari R, Burbiel JC, Hockemeyer J, Müller CE. Recent progress in the development of adenosine receptor ligands as antiinflammatory drugs. *Curr Top Med Chem*. 2006; 6:1375–1399. [PubMed: 16918456]
- Auchampach JA, Jin X, Wan TC, Caughey GH, Linden J. Canine mast cell adenosine receptors: cloning and expression of the A₃ receptor and evidence that degranulation is mediated by the A_{2B} receptor. *Mol Pharmacol*. 1997; 52:846–860. [PubMed: 9351976]

- Auchampach JA, Kreckler LM, Wan TC, Maas JE, van der Hoeven D, Gizewski E, Narayanan J, Maas GE. Characterization of the A_{2B} adenosine receptor from mouse, rabbit, and dog. *J Pharm Exp Ther*. 2009; 329:2–13.
- Balo MC, Brea J, Caamano O, Fernandez F, Garcia-Mera X, Lopez C, Loza MI, Nieto MI, Rodriguez-Borges JE. Synthesis and pharmacological evaluation of novel 1- and 8-substituted 3-furfurylxanthines as adenosine receptor antagonists. *Bioorg Med Chem*. 2009; 17:6755–6760. [PubMed: 19682912]
- Baraldi PG, Tabrizi MA, Preti D, Bovero A, Romagnoli R, Fruttarolo F, Zaid NA, Moorman AR, Varani K, Gessi S, Merighi S, Borea PA. Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A_{2B} adenosine receptor antagonists. *J Med Chem*. 2004; 47:1434–1447. [PubMed: 14998332]
- Baraldi PG, Preti D, Tabrizi MA, Fruttarolo F, Romagnoli R, Zaid NA, Moorman AR, Merighi S, Varani K, Borea PA. New pyrrolo[2,1-*f*]purine-2,4-dione and imidazo[2,1-*f*]purine-2,4-dione derivatives as potent and selective human A₃ adenosine receptor antagonists. *J Med Chem*. 2005; 48:4697–4701. [PubMed: 16000006]
- Baraldi PG, Tabrizi MA, Gessi S, Borea PA. Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility. *Chem Rev*. 2008; 108:238–263. [PubMed: 18181659]
- Barone S, Churchill PC, Jacobson KA. Adenosine receptor prodrugs: towards kidney-selective dialkylxanthines. *J Pharm Exp Therap*. 1989; 250:79–85.
- Bauer A, Ishiwata K. Adenosine receptor ligands and PET imaging of the CNS. *Handb Exp Pharmacol*. 2009; 193:617–642. [PubMed: 19639295]
- Baumgold J, Nikodijevic O, Jacobson KA. Penetration of adenosine antagonists into mouse brain as determined by ex vivo binding. *Biochem Pharmacol*. 1992; 43:889–894. [PubMed: 1540242]
- Bertarelli DCG, Diekmann M, Hayallah AM, Rüsing D, Iqbal J, Preiss B, Verspohl EJ, Müller CE. Characterization of human and rodent native and recombinant adenosine A_{2B} receptors by radioligand binding studies. *Purinergic Signal*. 2006; 2:559–571. [PubMed: 18404493]
- Bilkei-Gorzo A, Abo-Salem OM, Hayallah AM, Michel K, Müller CE, Zimmer A. Adenosine receptor subtype-selective antagonists in inflammation and hyperalgesia. *Naunyn Schmiedeberg Arch Pharmacol*. 2008; 377:65–76. [PubMed: 18188542]
- Blum D, Galas M-C, Pintor A, Brouillet E, Ledent C, Müller CE, Bantubungi K, Galluzzo M, Gall D, Cuvelier L, Rolland A-S, Popoli P, Schiffmann SN. A dual role of adenosine A_{2A} receptors in the modulation of 3-nitropropionic acid-induced striatal lesions: implications for the neuroprotective potential of A_{2A} antagonists. *J Neurosci*. 2003; 23:5361–5369. [PubMed: 12832562]
- Boring DL, Ji XD, Zimmet J, Taylor KE, Stiles GL, Jacobson KA. Trifunctional agents as a design strategy for tailoring ligand properties: Irreversible inhibitors of A₁ adenosine receptors. *Bioconjugate Chem*. 1991; 2:77–88.
- Borrmann T, Hinz S, Bertarelli DCG, Li W, Florin NC, Scheiff AB, Müller CE. 1-Alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A_{2B} receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity. *J Med Chem*. 2009; 52:3994–4006. [PubMed: 19569717]
- Brackett LE, Daly JW. Functional characterization of the A_{2b} adenosine receptor in NIH 3T3 fibroblasts. *Biochem Pharmacol*. 1994; 47:801–814. [PubMed: 8135856]
- Bridson SJ, Middleton RJ, Cordeaux Y, Flavin FM, Weinstein JA, George MW, Kellam B, Hill SJ. Quantitative analysis of the formation and diffusion of A₁-adenosine receptor-antagonist complexes in single living cells. *Proc Natl Acad Sci*. 2004; 101:4673–4678. [PubMed: 15070776]
- Bridson PK, Lin X, Mleman N, Ji XD, Jacobson KA. Synthesis and adenosine receptor affinity of 7-β-D-ribofuranosylxanthine. *Nucleosides Nucleotides*. 1998; 17:759–768. [PubMed: 9708335]
- Brooks DJ, Doder M, Osman S, Luthra SK, Hirani E, Hume S, Kase H, Kilborn J, Martindill S, Mori A. Positron emission tomography analysis of [¹¹C]KW-6002 binding to human and rat adenosine A_{2A} receptors in the brain. *Synapse*. 2008; 62:671–681. [PubMed: 18566974]
- Bruns RF. Adenosine antagonism by purines, pteridines and benzopteridines in human fibroblasts. *Biochem Pharmacol*. 1981; 30:325–333. [PubMed: 6260118]

- Bruns RF, Daly JW, Snyder SH. Adenosine receptors in brain membranes: binding of N⁶-cyclohexyl[³H]adenosine and 1,3-diethyl-8-[³H]phenylxanthine. *Proc Natl Acad Sci USA*. 1980; 77:5547–5551. [PubMed: 6254090]
- Bruns RF, Lu GH, Pugsley TA. Characterization of the A₂ adenosine receptor labeled by [³H]NECA in rat striatal membranes. *Mol Pharmacol*. 1986; 29:331–346. [PubMed: 3010074]
- Bruns RF, Lu GH, Pugsley TA. Topics and perspectives in adenosine research. Gerlach, E.; Becker, BF., editors. 1987a. p. 59
- Bruns RF, Fergus JH, Badger EW, Bristol JA, Santay LA, Hays SJ. PD 115,199: an antagonist ligand for adenosine A₂ receptors. *Naunyn Schmiedeberg Arch Pharmacol*. 1987b; 335:64–69. [PubMed: 3574493]
- Bruns RF, Fergus JH. Solubilities of adenosine antagonists determined by radioreceptor assay. *J Pharm Pharmacol*. 1989; 41:590–594. [PubMed: 2573701]
- Bulicz J, Bertarelli DCG, Baumert D, Fülle F, Müller CE, Heber D. Synthesis and pharmacology of pyrido[2,3-*d*]pyrimidinediones bearing polar substituents as adenosine receptor antagonists. *Bioorg Med Chem*. 2006; 14:2837–2849. [PubMed: 16377196]
- Burbiel J, Thorand M, Müller CE. Improved efficient synthesis for multigram-scale production of PSB-10, a potent antagonist at human A₃ adenosine receptors. *Heterocycles*. 2003; 60:1425–1432.
- Cacciari B, Pastorin G, Spalluto G. Medicinal chemistry of A_{2A} adenosine receptor antagonists. *Curr Top Med Chem*. 2003; 3:403–411. [PubMed: 12570758]
- Cagnina RE, Ramos SI, Marshall MA, Wang G, Frazier CR, Linden J. Adenosine A_{2B} receptors are highly expressed on murine type II alveolar epithelial cells. *Am J Physiol Lung Cell Mol Physiol*. 2009; 297:L467–L474. [PubMed: 19574419]
- Carotti A, Cadavid MI, Centeno NB, Esteve C, Loza MI, Martinez A, Nieto R, Ravina E, Sanz F, Segarra V, Sotelo E, Stefanachi A, Vidal B. Design, synthesis, and structure-activity relationships of 1-,3-,8- and 9-substituted 9-deazaxanthines at the human A_{2B} adenosine receptor. *J Med Chem*. 2006; 49:282–299. [PubMed: 16392813]
- Carriba P, Ortiz O, Patkar K, Justinova Z, Stroik J, Themann A, Müller C, Woods AS, Hope BT, Ciruela F, Casado V, Canela EI, Lluís C, Goldberg SR, Moratalla R, Franco R, Ferré S. Striatal adenosine A_{2A} and cannabinoid CB₁ receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. *Neuropsychopharmacology*. 2007; 32:2249–2259. [PubMed: 17356572]
- Ceccarelli S, Altobelli M, D'Alessandro A, Paesano A. A novel hydrophilic 8-cycloalkylxanthine derivative (IRFI 117) is a highly selective antagonist at A₁ adenosine receptors. *Res Commun Mol Pathol Pharmacol*. 1995; 87:101–102.
- Cirillo R, Barone D, Franzone JS. Doxofylline, an antiasthmatic drug lacking affinity for adenosine receptors. *Arch Int Pharmacodyn Ther*. 1988; 295:221–237. [PubMed: 3245738]
- Cohen BE, Lee G, Jacobson KA, Kim YC, Huang Z, Sorscher E, Pollard HB. CPX (1,3-dipropyl-8-cyclopentylxanthine) and other alkyl-xanthines differentially bind to wild type and DF508 mutant first nucleotide binding fold (NBF-1) domains of the cystic fibrosis transmembrane conductance regulator. *Biochemistry*. 1997; 36:6455–6461. [PubMed: 9174362]
- Cristalli G, Cacciari B, Dal Ben D, Lambertucci C, Moro S, Spalluto G, Volpini R. Highlights on the development of A_{2A} adenosine receptor agonists and antagonists. *ChemMedChem*. 2007; 2:260–281. [PubMed: 17177231]
- Cristalli, G.; Müller, CE.; Volpini, G. Recent development in adenosine A_{2A} receptor ligands. In: Wilson, CN.; Mustafa, SJ., editors. *Handbook of Experimental Pharmacology* 193: Adenosine Receptors in Health and Disease. 2009.
- Cunha GM, Canas PM, Melo CS, Hockemeyer J, Müller CE, Oliveira CR, Cunha RA. Adenosine A_{2A} receptor blockade prevents memory dysfunction caused by beta-amyloid peptides but not by scopolamine or MK-801. *Exp Neurol*. 2008; 210:776–781. [PubMed: 18191838]
- Dall'Igna OP, Fett P, Gomes MW, Souza DO, Cunha RA, Lara DR. Caffeine and adenosine A_{2A} receptor antagonists prevent beta-amyloid (25–35)-induced cognitive deficits in mice. *Exp Neurol*. 2007; 203:241–245. [PubMed: 17007839]
- Daly JW. Adenosine receptors: targets for future drugs. *J Med Chem*. 1982; 25:197–207. [PubMed: 6279840]

- Daly JW, Padgett W, Shamim MT, Butts-Lamb P, Waters J. 1,3-Dialkyl-8-(p-sulfophenyl)xanthines: potent water-soluble antagonists for A₁- and A₂-adenosine receptors. *J Med Chem.* 1985; 28:487–492. [PubMed: 2984420]
- Daly JW, Padgett WL, Shamim MT. Analogues of caffeine and theophylline: effect of structural alterations on affinity at adenosine receptors. *J Med Chem.* 1986a; 29:1305–1308. [PubMed: 3806581]
- Daly JW, Padgett WL, Shamim MT. Analogues of 1,3-dipropyl-8-phenylxanthine: enhancement of selectivity at A₁-adenosine receptors by aryl substituents. *J Med Chem.* 1986b; 29:1520–1524. [PubMed: 3016270]
- Daly JW, Hide I, Müller CE, Shamim M. Caffeine analogs: structure-activity relationships at adenosine receptors. *Pharmacology.* 1991; 42:309–321. [PubMed: 1658821]
- Daly JW. Analogs of caffeine and theophylline: activity as antagonists at adenosine receptors. In: Imai, S.; Nakazawa, M., editors. *Role of adenosine and adenine nucleotides in the biological system.* Elsevier; Amsterdam: 1991. p. 119–129.
- Daly JW.; Jacobson, KA. Adenosine and adenine nucleotides: from molecular biology to integrative physiology. Kluwer Academic Publishers; Boston: 1995. p. 155
- Daly JW. Alkylxanthines as research tools. *J Autonomic Nervous System.* 2000; 81:44–52.
- Daly JW. Caffeine analogs: biomedical impact. *Cell Mol Life Sci.* 2007; 64:2153–2169. [PubMed: 17514358]
- Del Giudice MR, Borioni A, Mustazza C, Gatta F, Dionisotti S, Zocchi C, Ongini E. (*E*)-1-(Heterocyclyl or cyclohexyl)-2-[1,3,7-trisubstituted(xanthin-8-yl)]ethenes as adenosine A_{2A} receptors antagonists. *Eur J Med Chem.* 1996; 31:59–63.
- Doggrell SA. BG-9928 (Biogen Idec). *Curr Opin Investig Drugs.* 2005; 6:962–968.
- Drabczynska A, Schumacher B, Müller CE, Karolak-Wojciechowska J, Michalak B, Pekala E, Kiec-Kononowicz K. Impact of the aryl substituent kind and distance from pyrimido[2,1-*f*]purindiones on the adenosine receptor selectivity and antagonistic properties. *Eur J Med Chem.* 2003; 38:397–402. [PubMed: 12750027]
- Drabczynska A, Müller CE, Schumacher B, Hinz S, Karolak-Wojciechowska J, Michalak B, Pekala E, Kiec-Kononowicz K. Tricyclic oxazolo[2,3-*f*]purinediones: potency as adenosine receptor ligands and anticonvulsants. *Bioorg Med Chem.* 2004; 12:4895–4908. [PubMed: 15336269]
- Drabczynska A, Müller CE, Lacher SK, Schumacher B, Karolak-Wojciechowska J, Nasal A, Kawczak P, Yuzlenko O, Pekala E, Kiec-Kononowicz K. Synthesis and biological activity of tricyclic arylimidazo-, pyrimido-, and diazepinopurinediones. *Bioorg Med Chem.* 2006; 14:7258–7281. [PubMed: 16844379]
- Drabczynska A, Müller CE, Karolak-Wojciechowska J, Schumacher B, Schiedel A, Yuzlenko O, Kiec-Kononowicz K. N⁹-Benzyl-substituted 1,3-dimethyl- and 1,3-dipropyl-pyrimido[2,1-*f*]purinediones: synthesis and structure-activity relationships at adenosine A₁ and A_{2A} receptors. *Bioorg Med Chem.* 2007a; 15:5003–5017. [PubMed: 17499511]
- Drabczynska A, Müller CE, Schiedel A, Schumacher B, Karolak-Wojciechowska J, Fruzinski A, Zobnina W, Yuzlenko O, Kiec-Kononowicz K. Phenylethyl-substituted pyrimido[2,1-*f*]purinediones and related compounds: structure-activity relationships as adenosine A₁ and A_{2A} receptor ligands. *Bioorg Med Chem.* 2007b; 15:6956–6974. [PubMed: 17827019]
- Elzein E, Kalla RV, Li X, Perry T, Gimbel A, Zeng D, Lustig D, Leung K, Zablocki J. Discovery of a novel A_{2B} adenosine receptor antagonist as a clinical candidate for chronic inflammatory airway diseases. *J Med Chem.* 2008; 51:2267–2278. [PubMed: 18321039]
- Erickson RH, Hiner RN, Feeney SW, Blake PR, Rzeszutarski WJ, Hicks RP, Costello DG, Abreu ME. 1,3,8-trisubstituted xanthines. Effects of substitution pattern upon adenosine receptor A₁/A₂ affinity. *J Med Chem.* 1991; 34:1431–1435. [PubMed: 2016719]
- Esteve C, Nueda JL, Beleta J, Cardenas A, Lozoya E, Cadavid MI, Loza MI, Ryder H, Vidal B. New pyrrolopyrimidin-6-ylbenzenesulfonamides: potent A_{2B} adenosine receptor antagonists. *Bioorg Med Chem Lett.* 2006; 16:3642–3645. [PubMed: 16697192]
- Farrar AM, Pereira M, Velasco F, Hockemeyer J, Müller CE, Salamone J. Adenosine A_{2A} receptor antagonism reverses the effects of dopamine receptor antagonism on instrumental output and

effort-related choice in the rat: implications for studies of psychomotor slowing. *Psychopharmacology*. 2007; 191:579–586. [PubMed: 17072593]

- Ferkany JW, Valentine HL, Stone GA, Williams M. Adenosine A₁ receptors in mammalian brain: species differences in their interactions with agonists and antagonists. *Drug Dev Res*. 1986; 9:85–93.
- Fernandez HH, Greeley DR, Zweig RM, Wojcieszek J, Mori A, Sussman NM. -US-051 Study Group (2010) Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial. *Parkinsonism Relat Disord*. 2010; 16:16–20. [PubMed: 19616987]
- Ferré S, Popoli P, Giménez-Llort L, Rimondini R, Müller CE, Strömberg I, Ögren SO, Fuxe K. Adenosine/dopamine interaction: implication for the treatment of Parkinson's disease. *Parkinsonism and Related Disorders*. 2001; 7:235–241. [PubMed: 11331192]
- Ferré S, Diamond I, Goldberg SR, Yao L, Hourani SM, Huang ZL, Urade Y, Kitchen I. Adenosine A_{2A} receptors in ventral striatum, hypothalamus and nociceptive circuitry implications for drug addiction, sleep and pain. *Prog Neurobiol*. 2007; 83:332–347. [PubMed: 17532111]
- Ferré S, Ciruela F, Borycz J, Solinas M, Quarta D, Antoniou K, Quiroz C, Justinova Z, Lluís C, Franco R, Goldberg SR. Adenosine A₁-A_{2A} receptor heteromers: new targets for caffeine in the brain. *Front Biosci*. 2008; 13:2391–2399. [PubMed: 17981720]
- Fhid O, Pawlowski M, Jurczyk S, Müller CE, Schumacher B. Pyridin-8-on[2,1-*f*]theophylline-9-alkylcarboxylic acid amides as A₁ and A_{2A} adenosine receptor ligands. *Il Farmaco*. 2003; 58:439–444. [PubMed: 12767383]
- Filip M, Frankowska M, Zaniewska M, Przegalinski E, Müller CE, Agnati LF, Franco R, Roberts DCS, Fuxe K. Involvement of adenosine A_{2A} and dopamine receptors in the locomotor and sensitizing effects of cocaine. *Brain Res*. 2006; 1077:67–80. [PubMed: 16516871]
- Fozard JR, Baur F, Wolber C. Antagonist pharmacology of adenosine A_{2B} receptors from rat, guinea pig and dog. *Eur J Pharmacol*. 2003; 475:79–84. [PubMed: 12954362]
- Franchetti P, Messini L, Cappellacci L, Grifantini M, Lucacchini A, Martini C, Senatore G. 8-Azaxanthine derivatives as antagonists of adenosine receptors. *J Med Chem*. 1994; 37:2970–2975. [PubMed: 8071944]
- Frédéric R, Ooms F, Castagnoli N Jr, Petzer JP, Feng JF, Schwarzschild MA, Van der Schyf CJ, Wouters J. (E)-8-(3-Chlorostyryl)-1,3,7-trimethylxanthine, a caffeine derivative acting both as antagonist of adenosine A_{2A} receptors and as inhibitor of MAO-B. *Acta Crystallogr*. 2005; C61:o531–o532.
- Fredholm BB, Abbracchio MP, Burnstock G, Daly JW, Harden KT, Jacobson KA, Leff P, Williams M. Nomenclature and classification of purinoceptors: a report from the IUPHAR subcommittee. *Pharmacol Rev*. 1994; 46:143–156. [PubMed: 7938164]
- Fredholm BB, Bättig K, Holmén J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. *Pharmacol Rev*. 1999; 51:83–133. [PubMed: 10049999]
- Fredholm BB, Jacobson KA. John W. Daly and the early characterization of adenosine receptors. *Heterocycles*. 2009; 79:73–83.
- Fuxe K, Marcellino D, Genedani S, Agnati L. Adenosine A_{2A} receptors, dopamine D₂ receptors and their interactions in Parkinson's disease. *Mov Disord*. 2007; 22:1990–2017. [PubMed: 17618524]
- Gao ZG, Kim SK, Biadatti T, Chen W, Lee K, Barak D, Kim SG, Johnson CR, Jacobson KA. Structural determinants of A₃ adenosine receptor activation: Nucleoside ligands at the agonist/antagonist boundary. *J Med Chem*. 2002; 45:4471–4484. [PubMed: 12238926]
- Geis U, Grahner B, Pawlowski M, Drabczynska A, Gorczyca M, Müller CE. Tricyclic theophylline derivatives with high water-solubility: structure-activity relationships at adenosine receptors, phosphodiesterases and benzodiazepine binding sites. *Pharmazie*. 1995; 50:333–336. [PubMed: 7604066]
- Givertz MM. Adenosine A₁ receptor antagonists at a fork in the road. *Circ Heart Fail*. 2009; 2:519–522. [PubMed: 19919975]
- Grahner B, Winiwarter S, Lanzner W, Müller CE. Synthesis and structure-activity relationships of deazaxanthines: analogs of potent A₁- and A₂-adenosine receptor antagonists. *J Med Chem*. 1994; 37:1526–1534. [PubMed: 8182711]

- Hayallah AM, Sandoval-Ramírez J, Reith U, Schobert U, Preiss B, Schumacher B, Daly JW, Müller CE. 1,8-Disubstituted xanthine derivatives: synthesis of potent A_{2B}-selective adenosine receptor antagonists. *J Med Chem.* 2002; 45:1500–1510. [PubMed: 11906291]
- Hauber W, Nagel J, Sauer R, Müller CE. Motor effects induced by a blockade of adenosine A_{2A} receptors in the caudate-putamen. *Neuroreport.* 1998; 9:1803–1806. [PubMed: 9665604]
- Hauber W, Neuscheler P, Nagel J, Müller CE. Catalepsy induced by a blockade of dopamine D₁ or D₂ receptors was reversed by a concomitant blockade of A_{2A} receptors in the caudate-putamen of rats. *Eur J Neurosci.* 2001; 14:1287–1293. [PubMed: 11703457]
- Hirani E, Gillies J, Karasawa A, Shimada J, Kase H, Opacka-Juffry J, Osman S, Luthra SK, Hume SP, Brooks DJ. Evaluation of [4-O-methyl-¹¹C]KW-6002 as a potential PET ligand for mapping central adenosine A_{2A} receptors in rats. *Synapse.* 2001; 42:164–176. [PubMed: 11746713]
- Hockemeyer J, Burbiel JC, Müller CE. Multigram-scale syntheses, stability, and photoreactions of A_{2A} adenosine receptor antagonists with 8-styrylxanthine structure: potential drugs for Parkinson's disease. *J Org Chem.* 2004; 69:3308–3318. [PubMed: 15132536]
- Holschbach MH, Olsson RA, Bier D, Wutz W, Sihver W, Schüller M, Palm B, Coenen HH. Synthesis and evaluation of no-carrier-added 8-cyclopentyl-3-(3-[¹⁸F]fluoropropyl)-1-propylxanthine ([¹⁸F]CPFPX): a potent and selective A₁-adenosine receptor antagonist for in vivo imaging. *J Med Chem.* 2002; 45:5150–5156. [PubMed: 12408725]
- Ilas J, Pekar S, Hockemeyer J, Euler H, Kirfel A, Müller CE. Development of spin-labeled probes for adenosine receptors. *J Med Chem.* 2005; 48:2108–2114. [PubMed: 15771453]
- Impagnatiello F, Bastia E, Ongini E, Monopoli A. Adenosine receptors in neurological disorders. *Emerg Ther Targets.* 2000; 4:635–663.
- Ishiwari K, Madson LJ, Farrar AM, Mingote SM, Valenta JP, DiGianvittorio MD, Frank LE, Correa M, Hockemeyer J, Müller CE, Salamone JD. Injections of the selective adenosine A_{2A} antagonist MSX-3 into the nucleus accumbens core attenuate the locomotor suppression induced by haloperidol in rats. *Behavioural Brain Res.* 2007; 178:190–199.
- Ishiwata K, Noguchi J, Toyama H, Sakiyama Y, Koike N, Ishii S, Oda K, Endo K, Suzuki F, Senda M. Synthesis and preliminary evaluation of [¹¹C]KF17837, a selective adenosine A_{2A} antagonist. *Appl Radiat Isot.* 1996; 47:507–511. [PubMed: 8673072]
- Ishiwata K, Sakiyama Y, Sakiyama T, Shimada J, Toyama H, Oda K, Suzuki F, Senda M. Myocardial adenosine A_{2A} receptor imaging of rabbit by PET with [¹¹C]KF17837. *Ann Nucl Med.* 1997; 11:219–225. [PubMed: 9310171]
- Ishiwata K, Noguchi J, Wakabayashi S, Shimada J, Ogi N, Nariai T, Tanaka A, Endo K, Suzuki F, Senda M. ¹¹C-labeled KF18446: a potential central nervous system adenosine A_{2A} receptor ligand. *J Nucl Med.* 2000a; 41:345–354. [PubMed: 10688121]
- Ishiwata K, Ogi N, Shimada J, Nonaka H, Tanaka A, Suzuki F, Senda M. Further characterization of a CNS adenosine A_{2A} receptor ligand [¹¹C]KF18446 with in vitro autoradiography and in vivo tissue uptake. *Ann Nucl Med.* 2000b; 14:81–89. [PubMed: 10830524]
- Ishiwata K, Shimada J, Wang WF, Harakawa H, Ishii S, Kiyosawa M, Suzuki F, Senda M. Evaluation of iodinated and brominated [¹¹C]styrylxanthine derivatives as in vivo radioligands mapping adenosine A_{2A} receptor in the central nervous system. *Ann Nucl Med.* 2000c; 14:247–253. [PubMed: 11023024]
- Ishiwata K, Ogi N, Hayakawa N, Oda K, Nagaoka T, Toyama H, Suzuki F, Endo K, Tanaka A, Senda M. Adenosine A_{2A} receptor imaging with [¹¹C]KF18446 PET in the rat brain after quinolinic acid lesion: comparison with the dopamine receptor imaging. *Ann Nucl Med.* 2002; 16:467–475. [PubMed: 12508837]
- Ishiwata K, Kawamura K, Kimura Y, Oda K, Ishii K. Potential of an adenosine A_{2A} receptor antagonist [¹¹C]TMSX for myocardial imaging by positron emission tomography: a first human study. *Ann Nucl Med.* 2003a; 17:457–462. [PubMed: 14575379]
- Ishiwata K, Wang WF, Kimura Y, Kawamura K, Ishii K. Preclinical studies on [¹¹C]TMSX for mapping adenosine A_{2A} receptors by positron emission tomography. *Ann Nucl Med.* 2003b; 17:205–211. [PubMed: 12846542]

- Ishiyama H, Nakajima H, Nakata H, Kobayashi J. Synthesis of hybrid analogues of caffeine and eudistomin D and their affinity for adenosine receptors. *Bioorg Med Chem*. 2009; 17:4280–4284. [PubMed: 19481943]
- Jacobson KA, Kirk KL, Padgett W, Daly JW. Probing the adenosine receptor with adenosine and xanthine biotin conjugates. *FEBS Lett*. 1985a; 184:30–35. [PubMed: 2985445]
- Jacobson KA, Kirk KL, Padgett WL, Daly JW. Functionalized congeners of 1,3-dialkylxanthines: preparation of analogues with high affinity for adenosine receptors. *J Med Chem*. 1985b; 28:1334–1340. [PubMed: 2993622]
- Jacobson KA, Ukena D, Kirk KL, Daly JW. [³H]xanthine amine congener of 1,3-dipropyl-8-phenylxanthine: an antagonist radioligand for adenosine receptors. *Proc Natl Acad Sci USA*. 1986a; 83:4089–4093. [PubMed: 3012550]
- Jacobson KA, Kirk KL, Padgett WL, Daly JW. A functionalized congener approach to adenosine receptor antagonists: amino acid conjugates of 1,3-dipropylxanthine. *Mol Pharmacol*. 1986b; 29:126–133. [PubMed: 3005825]
- Jacobson KA, Ukena D, Padgett W, Daly JW, Kirk KL. Xanthine functionalized congeners as potent ligands at A₂-adenosine receptors. *J Med Chem*. 1987a; 30:211–214. [PubMed: 3806597]
- Jacobson KA, Ukena D, Padgett W, Kirk KL, Daly JW. Molecular probes for extracellular adenosine receptors. *Biochem Pharmacol*. 1987b; 36:1697–1707. [PubMed: 3036153]
- Jacobson KA, Lipowski AW, Moody TW, Padgett W, Pijl E, Kirk KL, Daly JW. Binary drugs: conjugates of purines and a peptide that bind to both adenosine and substance P receptors. *J Med Chem*. 1987c; 30:1529–1532. [PubMed: 2441057]
- Jacobson KA, de la Cruz R, Schulick R, Kiriasis L, Padgett W, Pfeleiderer W, Kirk KL, Neumeyer JL, Daly JW. 8-Substituted xanthines as antagonists at A₁ and A₂-adenosine receptors. *Biochem Pharmacol*. 1988; 37:3653–3661. [PubMed: 3178879]
- Jacobson KA, Barone S, Kammula U, Stiles GL. Electrophilic derivatives of purines as irreversible inhibitors of A₁-adenosine receptors. *J Med Chem*. 1989a; 32:1043–1051. [PubMed: 2709373]
- Jacobson KA, Kiriasis L, Barone S, Bradbury BJ, Kammula U, Campagne JM, Daly JW, Neumeyer JL, Pfeleiderer W. Sulfur-containing xanthine derivatives as selective antagonists at A₁-adenosine receptors. *J Med Chem*. 1989b; 32:1873–1879. [PubMed: 2754711]
- Jacobson KA. Probing adenosine receptors using biotinylated purine conjugates. In: Wilchek, M.; Bayer, E., editors. *Methods in Enzymology*. Vol. 184. 1990. p. 668–671.
- Jacobson KA, van Galen PJM, Williams M. Perspective, adenosine receptors: pharmacology, structure activity relationships and therapeutic potential. *J Med Chem*. 1992a; 35:407–422. [PubMed: 1738138]
- Jacobson KA, Olah ME, Stiles GL. Trifunctional ligands: A radioiodinated high affinity acylating antagonist for the A₁ adenosine receptor. *Pharmacol Commun*. 1992b; 1:145–154.
- Jacobson KA, Gallo-Rodriguez C, Melman N, Fischer B, Maillard M, van Bergen A, van Galen PJ, Karton Y. Structure-activity relationships of 8-styrylxanthines as A₂-selective adenosine antagonists. *J Med Chem*. 1993a; 36:1333–1342. [PubMed: 8496902]
- Jacobson KA, Shi D, Gallo-Rodriguez C, Manning M Jr, Müller C, Daly JW, Neumeyer JL, Kiriasis L, Pfeleiderer W. Effect of trifluoromethyl and other substituents on activity of xanthines at adenosine receptors. *J Med Chem*. 1993b; 36:2639–2644. [PubMed: 8410976]
- Jacobson KA, Fischer B, Ji XD. A “cleavable trifunctional” approach to receptor affinity labeling: regeneration of binding to A₁-adenosine receptors. *Bioconjugate Chem*. 1995; 6:255–263.
- Jacobson KA. A₃ adenosine receptors: Novel ligands and paradoxical effects. *Trends Pharmacol Sci*. 1998; 19:184–191. [PubMed: 9652191]
- Jacobson KA, IJzerman AP, Linden J. 1,3-Dialkylxanthine derivatives having high potency as antagonists at human A_{2B} adenosine receptors. *Drug Devel Res*. 1999; 47:45–53.
- Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. *Nat Rev Drug Discov*. 2006; 5:247–264. [PubMed: 16518376]
- Jacobson KA. Functionalized congener approach to the design of ligands for G protein-coupled receptors (GPCRs). *Bioconjugate Chem*. 2009; 20:1816–1835.

- Jarvis MF, Jacobson KA, Williams M. Autoradiographic localization of adenosine A₁ receptors in rat brain using [³H]XCC, a functionalized congener of 1,3-dipropylxanthine. *Neurosci Lett*. 1987; 81:69–74. [PubMed: 3696476]
- Ji XD, Stiles GL, Jacobson KA. [³H]XAC (xanthine amine congener) is a radioligand for A₂-adenosine receptors in rabbit striatum. *Neurochem Internat*. 1991; 18:207–213.
- Ji XD, Gallo-Rodriguez C, Jacobson KA. 8-(3-Isothiocyantostyryl)caffeine is a selective irreversible inhibitor of striatal A₂-adenosine receptors. *Drug Devel Res*. 1993; 29:292–298. [PubMed: 22787287]
- Ji XD, von Lubitz D, Olah ME, Stiles GL, Jacobson KA. Species differences in ligand affinity at central A₃-adenosine receptors. *Drug Dev Res*. 1994; 33:51–59.
- Ji XD, Kim YC, Ahern DG, Linden J, Jacobson KA. [³H]MRS 1754, a selective antagonist radioligand for A_{2B} adenosine receptors. *Biochem Pharmacol*. 2001; 61:657–663. [PubMed: 11266650]
- Kalla R, Elzein E, Perry T, Li X, Gimbel A, Yang M, Zeng D, Zablocki J. Selective, high affinity A_{2B} adenosine receptor antagonists: N-1 monosubstituted 8-(pyrazol-4-yl)xanthines. *Bioorg Med Chem Lett*. 2008; 18:1397–1401. [PubMed: 18226896]
- Kalla R, Zablocki J. Progress in the discovery of selective, high affinity A_{2B} adenosine receptor antagonists as clinical candidates. *Purinergic Signal*. 2009; 5:21–29. [PubMed: 18568423]
- Karcz-Kubicha M, Quarta D, Hope BT, Antoniou K, Müller CE, Morales M, Schindler CW, Goldberg SR, Ferré S. Enabling role of adenosine A₁ receptors in adenosine A_{2A} receptor-mediated striatal expression of c-fos. *Eur J Neurosci*. 2003a; 18:296–302. [PubMed: 12887411]
- Karcz-Kubicha M, Antoniou K, Terasmaa A, Quarta D, Solinas M, Justinova Z, Pezzola A, Reggio R, Müller CE, Fuxe K, Goldberg SR, Popoli P, Ferré S. Involvement of adenosine A₁ and A_{2A} receptors in the motor effects of caffeine after its acute and chronic administration. *Neuropsychopharmacol*. 2003b; 28:1281–1291.
- Kase H. The adenosine A_{2A} receptor selective antagonist KW6002: research toward a novel nondopaminergic therapy for Parkinson's disease. *Neurology*. 2003; 61(Suppl 6):S97–S100. [PubMed: 14663020]
- Kiec-Kononowicz K, Drabczynska A, Pekala E, Michalak B, Müller CE, Schumacher B, Karolak-Wojciechowska J, Duddeck H, Rockitt S, Wartchow R. New developments in A₁ and A₂ adenosine receptor antagonists. *Pure Appl Chem*. 2001; 73:1411–1420.
- Kiesman WF, Zhao J, Conlon PR, Petter RC, Jin X, Smits G, Lutterodt F, Sullivan GW, Linden J. Norbornylactone-substituted xanthines as adenosine A₁ receptor antagonists. *Bioorg Med Chem*. 2006a; 14:3654–3661. [PubMed: 16458010]
- Kiesman WF, Zhao J, Conlon PR, Dowling JE, Petter RC, Lutterodt F, Jin X, Smits G, Fure M, Jayaraj A, Kim J, Sullivan G, Linden J. Potent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine A₁ receptor antagonists. *J Med Chem*. 2006b; 49:7119–7131. [PubMed: 17125264]
- Kim HO, Ji XD, Melman N, Olah ME, Stiles GL, Jacobson KA. Structure activity relationships of 1,3-dialkylxanthine derivatives at rat A₃-adenosine receptors. *J Med Chem*. 1994a; 37:3373–3382. [PubMed: 7932565]
- Kim, HO.; Ji, XD.; Melman, N.; Olah, ME.; Stiles, GL.; Jacobson, KA. Selective ligands for rat A₃-adenosine receptors: structure-activity relationships of 1,3-dialkylxanthine-7-riboside derivatives. 1994b.
- Kim YC, Karton Y, Ji XD, Melman N, Linden J, Jacobson KA. Acyl-hydrazide derivatives of a xanthine carboxylic congener (XCC) as selective antagonists at human A_{2B} adenosine receptors. *Drug Devel Res*. 1999; 47:178–188.
- Kim Y-S, Ji X-d, Melman N, Linden J, Jacobson KA. Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A_{2B} adenosine receptors. *J Med Chem*. 2000; 43:1165–1172. [PubMed: 10737749]
- Kim S-A, Marschall MA, Melman N, Kim HS, Müller CE, Linden J, Jacobson KA. Structure-activity relationships at human and rat A_{2B} adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. *J Med Chem*. 2002; 45:2131–2138. [PubMed: 12014951]

- Kirfel A, Schwabenländer F, Müller CE. Crystal structure of 1-propyl-8-(4-sulfophenyl)-7*H*-imidazo[4,5-*d*]pyrimidin-2,6(1*H*,3*H*)-dione dehydrate, C₁₄H₁₄N₄O₅S x 2 H₂O. *Z Kristallographie – New Cryst Struct*. 1997; 3:447–448.
- Klotz KN, Vogt H, Tawfik-Schlieper H. Comparison of adenosine receptors in brain from different species by radioligand binding and photoaffinity labelling. *Naunyn-Schmiedeberg's Arch Pharmacol*. 1991; 343:196–201. [PubMed: 2067592]
- Klotz KN, Hessling J, Hegler J, Owman C, Kull B, Fredholm BB, Lohse MJ. Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells. *Naunyn-Schmiedeberg's Arch Pharmacol*. 1998; 357:1–9. [PubMed: 9459566]
- Knutsen LJ, Weiss SM. KW-6002 (Kyowa Hakko Kogyo). *Curr Opin Investig Drugs*. 2001; 2:668–673.
- Krämer SD, Testa B. The biochemistry of drug metabolism – an introduction part 6. Inter-individual factors affecting drug metabolism. *Chem Biodivers*. 2008; 5:2465–2578. [PubMed: 19089818]
- Kull B, Arslan G, Nilsson C, Owman C, Lorenzen A, Schwabe U, Fredholm BB. Differences in the order of potency for agonists but not antagonists at human and rat adenosine A_{2A} receptors. *Biochem Pharmacol*. 1999; 57:65–75. [PubMed: 9920286]
- Linden J. Cloned adenosine A₃ receptors: pharmacological properties, species differences and receptor functions. *Trends Pharmacol Sci*. 1994; 15:298–306. [PubMed: 7940998]
- Linden J, Taylor HE, Robeva AS, Tucker AL, Stehle JH, Rivkees SA, Fink JS, Reppert SM. Molecular cloning and functional expression of a sheep A₃ adenosine receptor with widespread tissue distribution. *Mol Pharmacol*. 1993; 44:524–532. [PubMed: 8396714]
- Linden J, Thai T, Figler H, Jin X, Robeva AS. Characterization of human A_{2B} adenosine receptors: radioligand binding, western blotting, and coupling to G_q in human embryonic kidney 293 cells and HMC-1 mast cells. *Mol Pharmacol*. 1999; 56:705–713. [PubMed: 10496952]
- Marcellino D, Carriba P, Filip M, Borgkvist A, Frankowska M, Bellido I, Tanganelli S, Müller CE, Fisone G, Lluís C, Agnati LF, Franco R, Fuxe K. Antagonistic cannabinoid CB₁/dopamine D₂ receptor interactions in striatal CB₁/D₂ heteromers. A combined neurochemical and behavioural analysis. *Neuropharmacology*. 2008; 54:815–823. [PubMed: 18262573]
- Marian T, Boros I, Lengyel Z, Balkay L, Horvath G, Emri M, Sarkadi E, Szentmiklosi AJ, Fekete I, Tron L. Preparation and primary evaluation of [¹¹C]CSC as a possible tracer for mapping adenosine A_{2A} receptors by PET. *Appl Radiat Isot*. 1999; 50:887–893. [PubMed: 10214707]
- Martin PL, Wysocki RJ Jr, Barrett RJ, May JM, Linden J. Characterization of 8-(*N*-methylisopropyl)amino-*N*⁶-(5'-endohydroxy-endonorbornyl)-9-methyladenine (WRC-0571), a highly potent and selective, non-xanthine antagonist of A₁ adenosine receptors. *J Pharmacol Exp Ther*. 1996; 276:490–499. [PubMed: 8632314]
- Massip S, Guillon J, Bertarelli D, Bosc JJ, Leger JM, Lacher S, Bontemps C, Dupont T, Müller CE, Jarry C. Synthesis and preliminary evaluation of new 1- and 3-[1-(2-hydroxy-3-phenoxypropyl)]xanthines from 2-amino-2-oxazolines as potential A₁ and A_{2A} adenosine receptor antagonists. *Bioorg Med Chem*. 2006; 14:2697–2719. [PubMed: 16386423]
- Michael S, Warstat C, Michel F, Yan L, Müller CE, Nieber K. Adenosine A_{2A} agonist and A_{2B} antagonist mediate an inhibition of inflammation-induced contractile disturbance of a rat gastrointestinal preparation. *Purinergic Signal*. 2010 in press.
- Mishina M, Ishiwata K, Kimura Y, Naganawa M, Oda K, Kobayashi S, Katayama Y, Ishii K. Evaluation of distribution of adenosine A_{2A} receptors in normal human brain measured with [¹¹C]TMSX PET. *Synapse*. 2007; 61:778–784. [PubMed: 17568431]
- Moro S, Gao ZG, Jacobson KA, Spalluto G. Progress in the pursuit of therapeutic adenosine receptor antagonists. *Med Res Rev*. 2006; 26:131–159. [PubMed: 16380972]
- Mott AM, Nunes EJ, Collins LE, Port RG, Sink KS, Hockemeyer J, Müller CE, Salamone JD. The adenosine A_{2A} antagonist MSX-3 reverses the effects of the dopamine antagonist haloperidol on effort-related decision making in a T-maze cost/benefit procedure. *Psychopharmacology*. 2009; 204:103–112. [PubMed: 19132351]
- Müller CE. Formation of oxazolo[3,2-*a*]purinones from propynyluracils. *J Org Chem*. 1994; 59:1928–1929.

- Müller CE. A₁-Adenosine receptor antagonists. *Exp Opin Ther Patents*. 1997; 7:419–440.
- Müller CE. A_{2A} Adenosine receptor antagonists - future drugs for Parkinson's disease? *Drugs Fut*. 2000; 25:1043–1052.
- Müller CE. A₃ Adenosine receptor antagonists. *Mini-Rev Med Chem*. 2001; 1:417–427. [PubMed: 12369967]
- Müller CE. Medicinal chemistry of adenosine A₃ receptor ligands. *Curr Top Med Chem*. 2003; 3:445–462. [PubMed: 12570761]
- Müller CE. Prodrug approaches for enhancing the bioavailability of drugs with low solubility. *Chemistry & Biodiversity*. 2009; 6:2071–2083. [PubMed: 19937841]
- Müller CE, Scior T. Adenosine receptors and their modulators. *Pharm Acta Helv*. 1993a; 68:77–111. [PubMed: 8234392]
- Müller CE, Shi D, Manning M Jr, Daly JW. Synthesis of paraxanthine analogs (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: structure-activity relationships at adenosine receptors. *J Med Chem*. 1993b; 36:3341–3349. [PubMed: 8230124]
- Müller CE, Stein B. Adenosine receptor antagonists: structures and potential therapeutic applications. *Curr Pharm Des*. 1996; 2:501–530.
- Müller CE, Geis U, Hipp J, Schobert U, Frobenius W, Pawlowski M, Suzuki F, Sandoval-Ramirez J. Synthesis and structure-activity relationships of DMPX (3,7-dimethyl-1-propargylxanthine) derivatives, A_{2A}-selective adenosine receptor antagonists. *J Med Chem*. 1997a; 40:4396–4405. [PubMed: 9435909]
- Müller CE, Sauer R, Geis U, Frobenius W, Talik P, Pawlowski M. Aza-analogs of 8-styrylxanthines as A_{2A}-adenosine receptor antagonists. *Arch Pharm Pharm Med Chem*. 1997b; 330:181–189.
- Müller CE, Schobert U, Hipp J, Geis U, Frobenius W, Pawlowski M. Configurationally stable analogs of styrylxanthines as A_{2A} adenosine receptor antagonist. *Eur J Med Chem*. 1997c; 32:709–719.
- Müller CE, Sandoval-Ramirez J, Schobert U, Geis U, Frobenius W, Klotz KN. 8-(Sulfostyryl)xanthines: water-soluble A_{2A}-selective adenosine receptor antagonists. *Bioorg Med Chem*. 1998b; 6:707–719. [PubMed: 9681137]
- Müller CE, Maurinsh J, Sauer R. Binding of [³H]MSX-2 (3-(3-hydroxypropyl)-7-methyl-8-(*m*-methoxystyryl)-1-propargylxanthine) to rat striatal membranes - a new, selective antagonist radioligand for A_{2A} adenosine receptors. *Eur J Pharm Sci*. 2000; 10:259–265. [PubMed: 10838015]
- Müller CE, Thorand M, Qurishi R, Diekmann M, Jacobson KA, Padgett WL, Daly JW. Imidazo[2,1-*i*]purin-5-ones and related tricyclic water-soluble purine derivatives: potent A_{2A}- and A₃-adenosine receptor antagonists. *J Med Chem*. 2002a; 45:3440–3450. [PubMed: 12139454]
- Müller CE, Diekmann M, Thorand M, Ozola V. [³H]8-Ethyl-4-methyl-2-phenyl-(8*R*)-4,5,7,8-tetrahydro-1*H*-imidazo[2,1-*i*]purin-5-one ([³H]PSB-11), a novel high-affinity antagonist radioligand for human A₃ adenosine receptors. *Bioorg Med Chem Lett*. 2002b; 12:501–503. [PubMed: 11814828]
- Müller CE, Ferré S. Blocking striatal adenosine A_{2A} receptors: a new strategy for basal ganglia disorders. *Recent Patents CNS Drug Discov*. 2007; 2:1–21.
- Müller, CE.; Hockemeyer, J.; Tzvetkov, NT.; Burbiel, JC. Preparation of 8-ethynyl-xanthine derivatives as selective A_{2A} receptor antagonists (SANOL Arznei Schwarz GmbH, Germany). *PCT Int Appl*. WO 2008077557 A1. 2008.
- Nagel J, Schladebach H, Koch M, Schwienbacher I, Müller CE, Hauber W. Effects of an adenosine A_{2A} receptor blockade in the nucleus accumbens on locomotion, feeding, and prepulse inhibition in rats. *Synapse*. 2003; 49:279–286. [PubMed: 12827647]
- Nieto MI, Balo MC, Brea J, Caamano O, Cadavid MI, Fernandez F, Mera XG, Lopez C, Rodriguez-Borges JE. Synthesis of novel 1-alkyl-8-substituted 3-(3-methoxypropyl)xanthines as putative A_{2B} receptor antagonists. *Bioorg Med Chem*. 2009; 17:3426–3432. [PubMed: 19346133]
- Noguchi J, Ishiwata K, Furuat R, Simada J-i, Kiyosawa M, Ishii S-i, Endo K, Suzuki F, Senda M. Evaluation of carbon-11 labeled KF15372 and its ethyl and methyl derivatives as a potential CNS adenosine A₂ receptor ligand. *Nucl Med Biol*. 1997; 24:53–59. [PubMed: 9080475]

- Nonaka Y, Shimada J, Nonaka H, Koike N, Aoki N, Kobayashi H, Kase H, Yamaguchi K, Suzuki F. Photoisomerization of a potent and selective adenosine A₂ antagonist, (E)-1,3-Dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine. *J Med Chem.* 1993; 36:3731–3733. [PubMed: 8246243]
- Nonaka H, Ichimura M, Takeda M, Nonaka Y, Shimada J, Suzuki F, Yamaguchi K, Kase H. KF17837 ((E)-8-(3,4-dimethoxystyryl)-1,3-dipropyl-7-methylxanthine), a potent and selective adenosine A₂ receptor antagonist. *Eur J Pharmacol.* 1994a; 267:335–341. [PubMed: 8088373]
- Nonaka H, Mori A, Ichimura M, Shindou T, Yanagawa K, Shimada J, Kase H. Binding of [³H]KF17837S, a selective adenosine A₂ receptor antagonist, to rat brain membranes. *Mol Pharmacol.* 1994b; 46:817–822. [PubMed: 7969067]
- Obiefuna PC, Batra VK, Nadeem A, Borron A, Wilson CN, Mustafa SJ. A novel A₁ adenosine receptor antagonist, L-97-1 [3-[2-(4-aminophenyl)-ethyl]-8-benzyl-7-{2-ethyl-(2-hydroxy-ethyl)-amino}-ethyl]-1-propyl-3,7-dihydro-purine-2,6-dione], reduces allergic responses to house dust mite in an allergic rabbit model of asthma. *J Pharmacol Exp Ther.* 2005; 315:329–336. [PubMed: 16020631]
- Olah ME, Jacobson KA, Stiles GL. Affinity chromatography of the bovine cerebral cortex A₁ adenosine receptor. *FEBS Lett.* 1989; 257:292–296. [PubMed: 2583275]
- Ozola V, Thorand M, Diekmann M, Qurishi R, Schumacher B, Jacobson KA, Müller CE. 2-Phenylimidazo[2,1-*i*]purin-5-ones: structure-activity relationships and characterization of potent and selective inverse agonists at human A₃ adenosine receptors. *Bioorg Med Chem.* 2003; 11:347–356. [PubMed: 12517430]
- Park KS, Hoffmann C, Kim HO, Padgett WL, Daly JW, Brambilla R, Motta C, Abbracchio MP, Jacobson KA. Activation and desensitization of rat A₃-adenosine receptors by selective adenosine derivatives and xanthine-7-ribosides. *Drug Devel Res.* 1998; 44:97–105. [PubMed: 23487508]
- Pastorin G, Bolcato C, Cacciari B, Kachler S, Klotz K-N, Montopoli C, Moro S, Spalluto G. Synthesis, biological and modelling studies of 1,3-di-n-propyl-2,4-dioxo-6-methyl-8-(substituted) 1,2,3,4-tetrahydro[1,2,4]triazolo[3,4-*f*]purines as adenosine receptor antagonists. *Farmaco.* 2005; 60:643–651. [PubMed: 15961085]
- Patel A, Craig RH, Daluge SM, Linden J. 125I-BW-A844U, an antagonist radioligand with high affinity and selectivity for adenosine A₁ receptors, and ¹²⁵I-azido-BW-A844U, a photoaffinity label. *Mol Pharmacol.* 1988; 33:585–591. [PubMed: 3380075]
- Peet NP, Lentz NL, Dudley MW, Ogden AM, McCarty DR, Racke MM. Xanthines with C8 chiral substituents as potent and selective adenosine A₁ antagonists. *J Med Chem.* 1993; 36:4015–4020. [PubMed: 8258823]
- Petzer JP, Steyn S, Castagnoli KP, Chen JF, Schwarzschild MA, Van der Schyf CJ, Castagnoli N. Inhibition of monoamine oxidase B by selective adenosine A_{2A} receptor antagonists. *Bioorg Med Chem.* 2003; 11:1299–1310. [PubMed: 12628657]
- Petzer JP, Castagnoli N Jr, Schwarzschild MA, Chen J-F, Van der Schyf CJ. Dual-target-directed drugs that block monoamine oxidase B and adenosine A_{2A} receptors for Parkinson's disease. *Neurotherapeutics.* 2009; 6:141–151. [PubMed: 19110205]
- Pfister JR, Belardinelli L, Lee G, Lum RT, Milner P, Stanley WC, Linden J, Baker SP, Schreiner G. Synthesis and biological evaluation of the enantiomers of the potent and selective A₁-adenosine antagonist 1,3-dipropyl-8-[2-(5,6-epoxynorbornyl)]xanthine. *J Med Chem.* 1997; 40:1773–1778. [PubMed: 9191953]
- Pretorius J, Malan SF, Castagnoli N Jr, Bergh JJ, Petzer JP. Dual inhibition of monoamine oxidase B and antagonism of the adenosine A_{2A} receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues. *Bioorg Med Chem.* 2008; 16:8676–8684. [PubMed: 18723354]
- Priego E-M, von Frijtag Drabbe Kuenzel J, IJzerman AP, Camarasa M-J, Pérez-Pérez M-J. Pyrido[2,1-*f*]purine-2,4-dione derivatives as a novel class of highly potent human A₃ adenosine receptor antagonists. *J Med Chem.* 2002; 45:3337–3344. [PubMed: 12139445]
- Priego E-M, Pérez-Pérez M-J, von Frijtag Drabbe Kuenzel JK, de Vries H, IJzerman AP, Camarasa M-J, Martín-Santamaría S. Selective human adenosine A₃ antagonists based on pyrido[2,1-*f*]purine-2,4-diones: novel features of hA₃ antagonist binding. *ChemMedChem.* 2008; 3:111–119. [PubMed: 18000937]

- Richardson PJ, Kase H, Jenner PG. Adenosine A_{2A} receptor antagonists as new agents for the treatment of Parkinson's disease. *Trends Pharmacol Sci.* 1997; 18:338–344. [PubMed: 9345853]
- Robeva AS, Woodard RL, Jin X, Gao Z, Bhattacharya S, Taylor HE, Rosin DL, Linden J. Molecular characterization of recombinant human adenosine receptors. *Drug Dev Res.* 1996; 39:243–252.
- Saki M, Tsumuki H, Nonaka H, Shimada J, Ichimura M. KF26777 (2-(4-bromophenyl)-7,8-dihydro-4-propyl-1*H*-imidazo[2,1-*i*]purin-5(4*H*)-one dihydrochloride), a new potent and selective adenosine A₃ receptor antagonist. *Eur J Pharmacol.* 2002; 444:133–141. [PubMed: 12063073]
- Salamone JD, Betz AJ, Ishiwari K, Felsted J, Madson L, Mirante B, Clark K, Font L, Korbey S, Sager TN, Hockemeyer J, Müller CE. Tremorolytic effects of adenosine A_{2A} antagonists: implications for parkinsonism. *Front Biosci.* 2008; 13:3594–3605. [PubMed: 18508458]
- Salamone JD, Ishiwari K, Betz AJ, Farrar AM, Mingote SM, Font L, Hockemeyer J, Müller CE, Correa M. Dopamine/adenosine interactions related to locomotion and tremor in animal models: possible relevance to parkinsonism. *Parkinsonism Relat Disord.* 2008; 14(Suppl 2):S130–134. [PubMed: 18585081]
- Salvatore CA, Jacobson MA, Taylor HE, Linden J, Johnson RG. Molecular cloning and characterization of the human A₃ adenosine receptor. *Proc Natl Acad Sci USA.* 1993; 90:10365–10369. [PubMed: 8234299]
- Sauer R, Maurinsh J, Reith U, Fülle F, Klotz KN, Müller CE. Water-soluble phosphate prodrugs of 1-propargyl-8-styrylxanthine derivatives, A_{2A}-selective adenosine receptor antagonists. *J Med Chem.* 2000; 43:440–448. [PubMed: 10669571]
- Scammells PJ, Baker SP, Belardinelli L, Olsson RA. Substituted 1,3-dipropylxanthines as irreversible antagonists of A₁ adenosine receptors. *J Med Chem.* 1994; 37:2704–2712. [PubMed: 8064798]
- Schapira AH, Bezard E, Brotchie J, Calon F, Collingridge GL, Ferger B, Hengeler B, Hirsch E, Jenner P, Le Novère N, Obeso JA, Schwarzschild MA, Spampinato U, Davidai G. Novel pharmacological targets for the treatment of Parkinson's disease. *Nat Rev Drug Discov.* 2006; 5:845–854. [PubMed: 17016425]
- Schindler CW, Karcz-Kubicha M, Thorndike EB, Müller CE, Tella SR, Goldberg SR, Ferré S. Lack of adenosine A₁ and dopamine D₂ receptor-mediated modulation of the cardiovascular effects of the adenosine A_{2A} receptor agonist CGS 21680. *Eur J Pharmacol.* 2004; 484:269–275. [PubMed: 14744613]
- Schindler CW, Karcz-Kubicha M, Thorndike EB, Müller CE, Tella SR, Ferré S, Goldberg SR. Role of central and peripheral adenosine receptors in the cardiovascular responses to intraperitoneal injections of adenosine A₁ and A_{2A} subtype receptor agonists. *Br J Pharmacol.* 2005; 144:642–650. [PubMed: 15678095]
- Schingnitz G, Küfner-Mühl U, Ensinger H, Lehr E, Kuhn FJ. Selective A₁ antagonists for treatment of cognitive deficits. *Nucleosides Nucleotides.* 1991; 10:1067–1076.
- Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M. Targeting adenosine A_{2A} receptors in Parkinson's disease. *Trends Neurosci.* 2006; 29:647–654. [PubMed: 17030429]
- Seale TW, Abela KA, Shamim MT, Carney JM, Daly JW. 3,7-Dimethyl-1-propargylxanthine: a potent and selective in vivo antagonist of adenosine analogs. *Life Sci.* 1988; 43:1671–1684. [PubMed: 3193854]
- Shamim MT, Ukena D, Padgett WL, Hong O, Daly JW. 8-Aryl and 8-cycloalkyl-1,3-dipropylxanthines: further potent and selective antagonists for A₁-adenosine receptors. *J Med Chem.* 1988; 31:613–617. [PubMed: 3346878]
- Shamim MT, Ukena D, Padgett WL, Daly JW. Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-, and 7-positions. *J Med Chem.* 1989; 32:1231–1237. [PubMed: 2724296]
- Shimada J, Suzuki F, Nonaka H, Ishii A. 8-Polycycloalkyl-1,3-dipropylxanthines as potent and selective antagonists for A₁-adenosine receptors. *J Med Chem.* 1992a; 35:924–930. [PubMed: 1548682]
- Shimada J, Suzuki F, Nonaka H, Ishii A, Ichikawa S. (*E*)-1,3-Dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A₂ antagonists. *J Med Chem.* 1992b; 35:2342–2345. [PubMed: 1613758]

- Shimada J, Koike N, Nonaka H, Shiozaki S, Yanagawa K, Kanda T, Kobayashi H, Ichimura M, Nakamura J, Kase H, Suzuki F. Adenosine A_{2A} antagonists with potent anti-cataleptic activity. *Bioorg Med Chem Lett*. 1997; 7:2349–2352.
- Shukla D, Chakraborty S, Singh S, Mishra B. Doxofylline: a promising methylxanthine derivative for the treatment of asthma and chronic obstructive pulmonary disease. *Expert Opin Pharmacother*. 2009; 10:2343–2356. [PubMed: 19678793]
- Slawsky MT, Givertz MM. Rolofylline: a selective adenosine 1 receptor antagonist for the treatment of heart failure. *Expert Opin Pharmacother*. 2009; 10:311–322. [PubMed: 19236201]
- Solinas M, Ferré S, Antoniou K, Quarta D, Zustinova Z, Hockemeyer J, Pappas LA, Segal PN, Wertheim C, Müller CE, Goldberg SR. Involvement of adenosine A₁ receptors in the discriminative-stimulus effects of caffeine in rats. *Psychopharmacology*. 2005; 179:576–586. [PubMed: 15696333]
- Sorbera LA, Martín L, Castaner J. *Drugs Fut*. 2000; 25:1011–1016.
- Soriano A, Ventura R, Molero A, Hoen R, Casadó V, Cortés A, Fanelli F, Albericio F, Lluís C, Franco R, Royo M. Adenosine A_{2A} receptor-antagonist/dopamine D2 receptor agonist bivalent ligands as pharmacological tools to detect A_{2A}-D2 receptor heteromers. *J Med Chem*. 2009; 52:5590–5602. [PubMed: 19711895]
- Stefanachi A, Brea JM, Cadavid MI, Centeno NB, Esteve C, Loza MI, Martinez A, Nieto R, Ravina E, Sanz F, Segarra V, Sotelo E, Vidal B, Carotti A. 1-, 3- and 8-substituted 9-deazaxanthines as potent and selective antagonists at the human A_{2B} adenosine receptor. *Bioorg Med Chem*. 2008; 16:2852–2869. [PubMed: 18226909]
- Stefanovich V. The xanthines. *Drug News Perspect*. 1989; 2:82–88.
- Stiles GL, Jacobson KA. A new high affinity, iodinated adenosine receptor antagonist as a radioligand/photoaffinity crosslinking probe. *Mol Pharmacol*. 1987; 32:184–188. [PubMed: 3614192]
- Stiles GL, Jacobson KA. High affinity acylating antagonists for the A₁ adenosine receptor: identification of binding subunit. *Mol Pharmacol*. 1988; 34:724–728. [PubMed: 3200248]
- Stone GA, Jarvis MF, Sills M, Weeks B, Snowhill EW, Williams M. Species differences in high affinity adenosine A₂ receptors in striatal membranes from mammalian brain. *Drug Dev Res*. 1988; 15:31–46.
- Strömberg I, Popoli P, Müller CE, Ferré S, Fuxe K. Electrophysiological and behavioural evidence for an antagonistic modulatory role of adenosine A_{2A} receptors in dopamine D2 receptor regulation in the rat dopamine denervated striatum. *Eur J Neurosci*. 2000; 12:4033–4037. [PubMed: 11069599]
- Suzuki F, Shimada J, Mizumoto H, Karasawa A, Kubo K, Nonaka H, Ishii A, Kawakita T. Adenosine A₁ antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure. *J Med Chem*. 1992a; 35:3066–3075. [PubMed: 1501234]
- Suzuki F, Shimada J, Nonaka H, Ishii A, Shiozaki S, Ichikawa S, Ono E. 7,8-Dihydro-8-ethyl-2-(3-noradamantyl)-4-propyl-1*H*-imidazo[2,1-*i*]purin-5(4*H*)-one: a potent and water-soluble adenosine A₁ antagonist. *J Med Chem*. 1992b; 35:3578–3581. [PubMed: 1404238]
- Takahashi RN, Pamplona FA, Prediger RD. Adenosine receptor antagonists for cognitive dysfunction: a review of animal studies. *Front Biosci*. 2008; 13:2614–2632. [PubMed: 17981738]
- Thorsell A, Johnson J, Heilig M. Effect of the adenosine A_{2A} receptor antagonist 3,7-dimethyl-propargylxanthine on anxiety-like and depression-like behavior and alcohol consumption in Wistar Rats. *Alcohol Clin Exp Res*. 2007; 31:1302–1307. [PubMed: 17550371]
- Ukena D, Jacobson KA, Kirk KL, Daly JW. A [³H]amine congener of 1,3-dipropyl-8-phenylxanthine. A new radioligand for A₂ adenosine receptors of human platelets. *FEBS Lett*. 1986a; 199:269–274. [PubMed: 3009222]
- Ukena D, Jacobson KA, Padgett WL, Ayala C, Shamim MT, Kirk KL, Olsson RA, Daly JW. Species differences in structure-activity relationships of adenosine agonists and xanthine antagonists at brain A₁ adenosine receptors. *FEBS Lett*. 1986b; 209:122–128. [PubMed: 3803571]
- Ukena D, Daly JW, Kirk KL, Jacobson KA. Functionalized congeners of 1,3-dipropyl-8-phenylxanthine: potent antagonists for adenosine receptors that modulate membrane adenylate cyclase in pheochromocytoma cells, platelets and fat cells. *Life Sci*. 1986c; 38:797–807. [PubMed: 3005794]

- Ukena D, Schudt C, Sybrecht GW. Adenosine receptor-blocking xanthines as inhibitors of phosphodiesterase isozymes. *Biochem Pharmacol.* 1993; 45:847–851. [PubMed: 7680859]
- van den Berg D, Zoellner KR, Ogunrombi MO, Malan SF, Terre'Blanche G, Castagnoli N Jr, Bergh JJ, Petzer JP. Inhibition of monoamine oxidase B by selected benzimidazole and caffeine analogues. *Bioorg Med Chem.* 2007; 15:3692–3702. [PubMed: 17416530]
- van Galen PJM, van Bergen AH, Gallo-Rodriguez C, Melman N, Olah ME, IJzerman AP, Stiles GL, Jacobson KA. A binding site model and structure-activity relationships for the rat A₃ adenosine receptor. *Mol Pharmacol.* 1994; 45:1101–1111. [PubMed: 8022403]
- van Muijlwijk-Koezen JE, Timmerman H, van der Sluis RP, van de Stolpe AC, Menge WM, Beukers MW, van der Graaf PH, de Groote M, IJzerman AP. Synthesis and use of FSCPX, an irreversible adenosine A₁ antagonist, as a 'receptor knock-down' tool. *Bioorg Med Chem.* 2001; 11:815–818.
- Vittori S, Volpini R, Lambertucci C, Taffi S, Klotz KN, Cristalli G. 2-substituted 5'-N-methylcarboxamidoadenosine (MECA) derivatives as A₃ adenosine receptor ligands. *Nucleosides Nucleotides Nucleic Acids.* 2005; 24:935–938. [PubMed: 16248066]
- Vlok N, Malan SF, Castagnoli N Jr, Bergh JJ, Petzer JP. Inhibition of monoamine oxidase B by analogues of the adenosine A_{2A} receptor antagonist (E)-8-(3-chlorostyryl)caffeine (CSC). *Bioorg Med Chem.* 2006; 14:3512–2351. [PubMed: 16442801]
- Vollmann K, Qurishi R, Hockemeyer J, Müller CE. Synthesis and properties of a new water-soluble prodrug of the adenosine A_{2A} receptor antagonist MSX-2. *Molecules.* 2008; 13:348–359. [PubMed: 18305423]
- Vu CB. Recent advances in the design and optimization of adenosine A_{2A} receptor antagonists. *Curr Opin Drug Discov Devel.* 2005; 8:458–468.
- Vu CB, Kiesman WF, Conlon PR, Lin K-C, Tam M, Petter RC, Smits G, Lutterodt F, Jin X, Chen L, Zhang J. Tricyclic imidazoline derivatives as potent and selective adenosine A₁ receptor antagonists. *J Med Chem* (2006). 2006; 49:7132–7139.
- Weiss HM, Grisshammer R. Purification and characterization of the human adenosine A_{2A} receptor functionally expressed in *Escherichia coli*. *Eur J Biochem.* 2002; 269:82–92. [PubMed: 11784301]
- Weyler S, Fülle F, Diekmann M, Schumacher B, Hinz S, Klotz KN, Müller CE. Improving potency, selectivity, and water-solubility of adenosine A₁ receptor antagonists: xanthines modified at position 3 and related pyrimido[1,2,3-*cd*]purinediones. *ChemMedChem.* 2006; 1:891–902. [PubMed: 16902942]
- Worden L, Shahriari M, Farrar A, Sink KS, Hockemeyer J, Müller CE, Salamone JD. The adenosine A_{2A} antagonist MSX-3 reverses the effort-related effects of dopamine blockade: differential interaction with D₁ and D₂ family antagonists. *Psychopharmacology.* 2009; 203:489–499. [PubMed: 19048234]
- Yan L, Müller CE. Preparation, properties, reactions, and adenosine receptor affinities of sulfophenylxanthine nitrophenyl esters: toward the development of sulfonic acid prodrugs with peroral bioavailability. *J Med Chem.* 2004; 47:1031–1043. [PubMed: 14761205]
- Yan L, Bertarelli CG, Hayallah AM, Meyer H, Klotz KN, Müller CE. A new synthesis of sulfonamides by aminolysis of *p*-nitrophenylsulfonates yielding potent and selective adenosine A_{2B} receptor antagonists. *J Med Chem.* 2006; 49:4384–4391. [PubMed: 16821798]
- Yu L, Shen HY, Coelho JE, Araujo IM, Huang QY, Day YJ, Rebola N, Canas PM, Rapp EK, Ferrara J, Taylor D, Müller CE, Linden J, Cunha RA, Chen JF. Adenosine A_{2A} receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. *Ann Neurol.* 2008; 63:338–346. [PubMed: 18300283]
- Yuzlenko O, Kiec-Kononowicz K. Potent adenosine A₁ and A_{2A} receptors antagonists: recent developments. *Curr Med Chem.* 2006; 13:3609–3625. [PubMed: 17168726]
- Zablocki J, Kalla R, Perry T, Palle V, Varkhedkar V, Xiao D, Piscopio A, Maa T, Gimbel A, Hao J, Chu N, Leung K, Zeng D. The discovery of a selective, high affinity A_{2B} adenosine receptor antagonist for the potential treatment of asthma. *Bioorg Med Chem.* 2005; 15:609–612.

Fig. 1.
8-Unsubstituted xanthine derivatives

Fig. 2.
8-Phenyl- and 8-phenylalkyl-substituted xanthines and heteroaromatically substituted derivatives

Fig. 3.
8-Cycloalkylxanthines

Fig. 4.
8-Styrylxanthines and configurationally stable analogs

Fig. 5.
Deaxanthines and azaxanthines

Fig. 6.
Tricyclic xanthine derivatives

Fig. 7.
Functionalized xanthenes as molecular probes

Table 1

Adenosine receptor affinities of 8-unsubstituted xanthine derivatives

		K_i (nM) ^a			
		A ₁	A _{2A}	A _{2B}	A ₃
Natural xanthine (X) derivatives					
1	Caffeine (1,3,7-TrimethylX)	10,700 (h) ¹ 44,900 (h) ² 41,000 (r) ³ 44,000 (r) ⁴ 47,000 (gp) ⁵ 44,000 (c) ⁵	23,400 (h) ² 9,560 (h) ¹ 45,000 (r) ⁴ 32,500 (r) ⁶ 48,000 (r) ¹	33,800 (h) ⁷ 10,400 (h) ⁸ 20,500 (h) ⁹ 30,000 (r) ¹⁰ 13,000 (m) ¹⁰	13,300 (h) ¹ >100,000 (r) ¹¹
2	Theophylline (1,3-DimethylX)	6,770 (h) ¹² 14,000 (r) ¹³ 8,740 (r) ¹ 7,060 (gp) ¹⁴ 4,710 (rb) ¹⁴ 9,050 (s) ¹⁴ 6,330 (c) ¹⁴	1,710 (h) ¹² 6,700 (h) ¹ 22,000 (r) ¹³ 25,300 (r) ¹	9,070 (h) ⁸ 74,000 (h) ⁹ 15,100 (r) ⁸ 5,630 (m) ¹⁵ 11,000 (gp) ¹⁶ 17,700 (rb) ¹⁵ 38,700 (d) ¹⁵	22,300 (h) ¹ 86,400 (h) ¹² >100,000 (r) ¹¹ 85,000 (r) ¹⁷ >100,000 (d) ¹⁸
3	Theobromine (3,7-DimethylX)	105,000 (r) ¹³ 83,400 (r) ¹⁹	>250,000 (r) ¹³ 187,000 (r) ¹⁹	130,000 (h) ¹⁹	>100,000 (r) ¹¹
4	Paraxanthine (1,7-DimethylX)	21,000 (r) ¹³	32,000 (r) ¹³	4,500 (h) ²⁰	>100,000 (r) ¹¹
Mono-substituted xanthine derivatives					
5	1-MethylX	36,000 (r) ¹³ 11,400 (r) ¹⁹	47,000 (r) ¹³ 36,200 (r) ¹⁹	6,600 (h) ¹⁹	>100,000 (r) ¹¹
6	1-PropylX	13,000 (r) ¹³	33,000 (r) ¹³	360 (h) ⁸ 1,880 (r) ⁸	2,370 (h) ⁸
7	1-ButylX	9,000 (r) ¹³	61,000 (r) ¹³	421 (h) ⁸	4,610 (h) ⁸
8	1-BenzylX	2,800 (r) ¹³	22,000 (r) ¹³	nd	nd
9	3-MethylX	>100,000 (r) ¹³ 35,000 (r) ²¹	59,000 (r) ¹³	87,000 (h) ²⁰	>100,000 (r) ¹¹
10	Epropylxanthine (3-PropylX)	156,000 (h) ²² 42,000 (h) ¹ 32,000 (r) ¹³	32,000 (h) ²² 81,300 (h) ¹ 137,000 (r) ¹³	7,000 (h) ²² 4,730 (h) ⁸ 19,800 (h) ²³	92,600 (h) ¹ 65,000 (h) ²² 93,000 (r) ¹

		K_i (nM) ^a			
		A ₁	A _{2A}	A _{2B}	A ₃
		29,100 (r) ^{/9} >100,000 (d) ^{/8}	103,000 (r) ^{/9}	26,000 (r) ^{/24} 5,630 (m) ^{/15} 5,840 (rb) ^{/15} 6,960 (d) ^{/15}	>100,000 (d) ^{/18}
11	7-MethylX	33,000 (r) ^{/13}	59,000 (r) ^{/13}	97,000 (h) ^{/20}	>100,000 (r) ^{/11}
12	7-PropylX	18,000 (r) ^{/13}	>200,000 (r) ^{/13}	nd	nd
13	9-MethylX	>250,000 (r) ^{/13}	>250,000 (r) ^{/13}	>1,000,000 (h) ^{/20}	>100,000 (r) ^{/11}
14	9-PropylX	>250,000 (r) ^{/13}	>250,000 (r) ^{/13}	nd	nd
Di- and trisubstituted xanthine derivatives					
15	Doxofylline	ca. 100,000 ²⁵	ca. 100,000 ²⁵	nd	nd
16	1,3-DipropylX	700 (r) ^{/13} 450 (r) ^{/9} 1,310 (gp) ⁵ 340 (c) ⁵	6,600 (r) ^{/13} 5,160 (r) ^{/9}	1,110 (h) ⁸ 680 (h) ^{/20}	1,940 (h) ^{/1}
17 IBMX	3-Isobutyl-1-methylX	7,000 (r) ^{/13} 2,460 (r) ^{/9} 8,600 (gp) ⁵ 4,400 (c) ⁵	16,000 (r) ^{/13} 13,800 (r) ^{/9}	3,500 (h) ^{/9}	nd
18	3-Methyl-1-propargylX	820 (r) ^{/13} 5,830 (r) ⁸	4,800 (r) ^{/13} 33,600 (r) ⁸	511 (h) ⁸ 2,150 (r) ⁸	10,900 (h) ⁸
19	7-Methyl-1-propargylX	22,000 (r) ^{/13}	16,000 (r) ^{/13}	nd	nd
20 DMPX	3,7-Dimethyl-1-propargylX	45,000 (r) ⁴ 11,000 (r) ⁵ 25,800 (gp) ⁵ 16,400 (c) ⁵	16,000 (r) ⁴ 5,600 (r) ⁶	4,130 (h) ⁸	>10,000 (r) ²⁶
21	DBXR	4,190 (r) ^{/1}	19,500 (r) ^{/11}	nd	6,030 (r) ^{/11,b}
22	DBXRM	37,300 (r) ²⁷	>100,000 (r) ²⁷	nd	229 (r) ^{27,c}

^a h = human; c = cow; d = dog; gp = guinea pig; m = mouse; r = rat; rb = rabbit; a few A_{2B} data are from functional (cAMP) studies; nd = no data available

^b partial agonist;

- ^c full agonist
- ¹ Jacobson et al., 1999
- ² Abo-Salem et al., 2004
- ³ Grahner et al., 1994
- ⁴ Daly et al., 1991
- ⁵ Ukena et al., 1986b
- ⁶ Müller et al., 2000
- ⁷ Bormann et al., 2009
- ⁸ Kim et al., 2002
- ⁹ Bertarelli et al., 2006
- ¹⁰ Brackett and Daly, 1994
- ¹¹ van Galen et al., 1994
- ¹² Klotz et al., 1998
- ¹³ Müller et al., 1993b
- ¹⁴ Klotz et al., 1991
- ¹⁵ Auchampach et al., 2009
- ¹⁶ Fozard et al., 2003
- ¹⁷ Jacobson et al., 1995
- ¹⁸ Auchampach et al., 1997
- ¹⁹ Bruns et al., 1986
- ²⁰ Bruns, 1981
- ²¹ Shamim et al., 1989
- ²² Robeva et al., 1996
- ²³ Ji et al., 2001
- ²⁴ Alexander et al., 1996

²⁵ Cirillo et al., 1988

²⁶ Müller et al., 2007

²⁷ Kim et al., 1994b

Table 2

Adenosine receptor affinities of 8-phenyl- and 8-phenylalkyl-substituted xanthenes and heteroaromatically substituted derivatives

		K _i (nM) ^a			
		A ₁	A _{2A}	A _{2B}	A ₃
First-generation 8-phenylxanthine derivatives					
23	8-PhenylX	2,500 (r) ¹	21,000 (r) ¹	810 (h) ²	nd
24	8-Phenyl-theophylline (8-PT)	1,340 (h) ³ 115 (h) ⁴ 86 (r) ⁵ 76 (r) ⁶ 1,540 (gp) ⁶ 7.6 (c) ⁶	454 (h) ³ 850 (r) ⁵	415 (h) ⁷ 436 (m) ⁸ 249 (tb) ⁸ 371 (d) ⁸	1,250 (h) ³ >100,000 (r) ⁹
25	1,3-Diethyl-8-phenylX (DPX)	44 (r) ¹⁰	860 (r) ¹⁰ 190 (h) ¹¹	62.0 (h) ⁷	nd
26	1,3-Dipropyl-8-phenylX	10 (r) ⁶ 0.22 (c) ⁶ 20.9 (gp) ⁶	180 (r) ¹² 2100 (h) ¹³	18.9 (h) ⁷	nd
27	SPT	1,000 (h) ³ 4,500 (r) ⁵ 1,000 (r) ⁶ 10,100 (gp) ⁶ 6,460 (d) ¹⁴ 300 (c) ⁶	7,050 (h) ³ 14,000 (r) ⁵	1,330 (h) ⁷ 1,590 (r) ¹⁵ 4,990 (m) ⁸ 2,190 (gp) ¹⁵ 2,370 (tb) ⁸ 7,240 (d) ⁸ 224 (d) ¹⁵	5,890 (h) ¹⁶ 11,000 (h) ¹⁷ ≥10,000 (r) ¹⁶ 25,300 (d) ¹⁴
28	DPSPX	210 (r) ⁵ 140 (r) ⁹	1,400 (r) ⁵ 790 (r) ⁹	568 (m) ⁸ 200 (tb) ⁸ 721 (d) ⁸	183 (s) ¹⁸ >100,000 (r) ⁹ 22,500 (tb) ¹⁹
29		12 (r) ²⁰	83 (r) ²⁰	nd	nd
30	XAC	6.8 (h) ²¹ 29.1 (h) ²² 1.2 (r) ²³ 0.49 (r) ¹⁹ 5.49 (gp) ¹⁹ 0.45 (tb) ¹⁹ 0.09 (s) ¹⁹	18 (h) ²¹ 1,00 (h) ²² 63 (r) ²³	7.8 (h) ²³ 16.0 (h) ⁷ 42.7 (r) ¹⁵ 4.51 (m) ⁸ 17.8 (gp) ¹⁵ 4.47 (tb) ⁸ 29.8 (d) ⁸	91.9 (h) ²² 26 (h) ²¹ 71 (h) ¹⁴ 29,000 (r) ¹⁴ 106 (tb) ¹⁴ 180 (s) ^{18,24} 138 (d) ¹⁴

		K_i (nM) ^a			
		A ₁	A _{2A}	A _{2B}	A ₃
		0.03 (c) ¹⁹ 159 (d) ¹⁴		3.55 (d) ¹⁵	
31	PD113,297	5.59 (r) ¹²	70.0 (r) ¹²	nd	nd
32	PD115,199	14 (r) ²⁵ 4.05 (r) ²⁰	16 (r) ²⁵ 3.86 (rb) ²⁶	160 (m) ²⁷	nd
33	NPC-205	3.5 (r) ²⁸	48 (h) ²⁸	50 (gp) ²⁹	nd
34	I-ABOPX (BW-A522)	70 (h) ⁴⁵ 37 (r) ³⁰ 601 (d) ¹⁴	95 (h) ⁴⁵ 700 (r) ³⁰	30 (h) ⁴⁵	18 (h) ²⁴ 1,170 (r) ³¹ 1,500 (r) ¹⁴ 179 (rb) ¹⁴ 37.5 (d) ¹⁴
35	BWA1433	20 (r) ³⁰ 132 (d) ¹⁴	nd	15.6 (h) ⁴⁵	54 (h) ²⁴ 15,000 (r) ¹⁴ 384 (rb) ¹⁴ 1,880 (d) ¹⁴
36	XCC	175 (h) ²¹ 58 (r) ²³	2200 (h) ²¹ 595 (h) ²¹	13.6 (h) ²³ 40 (h) ⁷ 2,200 (r) ²³	3,910 (h) ²¹ 75,700 (r) ²¹
A_{2B}-selective 8-phenylxanthine derivatives and heteroaromatically substituted derivatives					
37	MRS1754	403 (h) ²¹ 16.8 (r) ²¹	503 (h) ²¹ 612 (r) ²¹	1.97 (h) ²¹ 12.8 (r) ²¹ 16.6 (r) ¹⁵ 3.39 (m) ⁸ 9.12 (gp) ¹⁵ 1.79 (rb) ⁸ 12.8 (d) ⁸ 12.3 (d) ¹⁵	570 (h) ²¹
38	MRS1706	157 (h) ²¹ 38 (r) ²¹	112 (h) ²¹ 548 (r) ²¹	1.4 (h) ²¹	230 (h) ²¹
39	MRS1765	152 (h) ²¹ 15.7 (r) ²¹	293 (h) ²¹ 1640 (r) ²¹	2.13 (h) ²¹	1270 (h) ²¹
40	CVT-5440	>10,000 (h) ³²	>10,000 (h) ³²	50 (h) ³²	>10,000 (h) ³²

		K _i (nM) ^a				
		A ₁	A _{2A}	A _{2B}	A ₃	
		3,030 (h) ^{2I} 11.1 (r) ^{2I}	1,970 (h) ^{2I} 126 (r) ^{2I}	26.6 (h) ^{2I}	670 (h) ^{2I}	
41	MRS1595					
42		100 (r) ³³	97.7 (h) ³³	2.88 (h) ³³	1,290 (h) ³³	
43	PSB-1115	>10,000 (h) ² 2,200 (r) ^I	24,000 (r) ^I	53.4 (h) ²	>10,000 (h) ²	
44	PSB-50	60 (r) ²	199 (r) ²	6.8 (h) ²	477 (h) ²	
45	PSB-53	1,181 (h) ² 481 (r) ²	ca. 10,000 (h) ² 3,800 (r) ²	24 (h) ²	4,622 (h) ²	
46	PSB-55	122 (h) ² 37 (r) ²	ca. 10,000 (r) ² 550 (r) ²	1.3 (h) ²	475 (h) ²	
47	PSB-298	68 (h) ² 35 (r) ²	2,139 (r) ²	1.2 (h) ² 60 (h) ³⁴	422 (h) ²	
48		3.6 (r) ³⁵	74 (r) ³⁵	5.4 (h) ³⁵	10,000 (h) ³⁵	
49	PSB-601	2,067 (h) ³⁶ 260 (r) ³⁶	484 (h) ³⁶ 93.7 (r) ³⁶	3.6 (h) ³⁶	>1,000 (h) ³⁶	
50	PSB-09120	>10,000 (h) ³⁷ >1,000 (r) ³⁷	22.7 (h) ³⁷ 122 (r) ³⁷	0.157 (h) ³⁷	>10,000 (h) ³⁷	
51	PSB-0788	2,240 (h) ³⁷ 386 (r) ³⁷	333 (h) ³⁷ 1,730 (r) ³⁷	0.393 (h) ³⁷	>1,000 (h) ³⁷	
52	PSB-603	>10,000 (h) ³⁷ >10,000 (r) ³⁷	>10,000 (h) ³⁷ >10,000 (r) ³⁷	0.553 (h) ³⁷ K _D 0.403 (h) ³⁷ K _D 0.351 (m) ³⁷	>10,000 (h) ³⁷	
53	CVT-6694	>6,000 (h) ³⁸	>5,000 (h) ³⁸	7 (h) ³⁸	>9,000 (h) ³⁸	
54	CVT-7124	>6,000 (h) ³⁸	>5,000 (h) ³⁸	6 (h) ³⁸	>9,000 (h) ³⁸	
55	CVT-6883	1,940 (h) ³⁹	3,280 (h) ³⁹	22 (h) ³⁹	1,070 (h) ³⁹	
56	MRE-2029-F20	200 (h) ⁴⁰	>1,000 (h) ⁴⁰	5.5 (h) ⁴⁰	>1,000 (h) ⁴⁰	
57	ATL 802	369 (h) ⁴¹ 9,583 (m) ⁴¹	654 (h) ⁴¹ 8,393 (m) ⁴¹	2.36 (h) ⁴¹ 8.58 (m) ⁴¹	>1,000 (h) ⁴¹ >10,000 (m) ⁴¹	

		K _i (nM) ^a			
		A ₁	A _{2A}	A _{2B}	A ₃
58	ATL 852	nd	nd	28.5 (h) ^c	nd
8-Phenylalkyl-substituted xanthines					
59	MDL 102,503	6.9 (r) ⁴²	157 (r) ⁴²	nd	nd
60		60.7 (r) ⁴²	848 (r) ⁴²	nd	nd
61	MDL 102,234	23.2 (r) ⁴²	3,510 (r) ⁴²	nd	nd
62	L-97-1	580 (h) ⁴³	>100,000 (h) ⁴³	>100,000 (h) ⁴³	nd
63		102 (r) ⁴⁴	83.2 (h) ⁴⁴	7.41 (h) ⁴⁴	10,000 (h) ⁴⁴

^ah = human; c = cow; d = dog; gp = guinea pig; m= mouse; r = rat; rb = rabbit; a few A2B data are from functional (cAMP) studies; nd = no data available;

^c personal communication (J. Linden), also see ⁴¹

- ¹ Müller et al., 1993b
- ² Hayallah et al., 2002
- ³ Kim et al., 1999
- ⁴ Ferkany et al., 1986
- ⁵ Daly, 1991
- ⁶ Ukena et al., 1986b
- ⁷ Kim et al., 2002
- ⁸ Auchampach et al., 2009
- ⁹ van Galen et al., 1994
- ¹⁰ Bruns et al., 1987
- ¹¹ Ukena et al., 1986a
- ¹² Bruns et al., 1986
- ¹³ Shamim et al., 1989
- ¹⁴ Auchampach et al., 1997

- ¹⁵ Fozard et al., 2003
- ¹⁶ Abo-Salem et al., 2004
- ¹⁷ Martin et al., 1996
- ¹⁸ Linden et al., 1993
- ¹⁹ Klotz et al., 1991
- ²⁰ Jacobson et al., 1988
- ²¹ Kim et al., 2000
- ²² Klotz et al., 1998
- ²³ Jacobson et al., 1999
- ²⁴ Salvatore et al., 1993
- ²⁵ Bruns et al., 1987a
- ²⁶ Ji et al., 1991
- ²⁷ Brackett and Daly, 1994
- ²⁸ Shamim et al., 1988
- ²⁹ Daly et al., 1986b
- ³⁰ Linden, 1994
- ³¹ Kim et al., 1994a
- ³² Zablocki et al., 2005
- ³³ Nieto et al., 2009
- ³⁴ Bertarelli et al., 2006
- ³⁵ Yan et al., 2004
- ³⁶ Yan et al., 2006
- ³⁷ Bormann et al., 2009
- ³⁸ Kalla et al., 2008
- ³⁹ Elzein et al., 2008

- ⁴⁰ Baraldi et al., 2004
- ⁴¹ Cagnina et al., 2009
- ⁴² Peet et al., 1993
- ⁴³ Obiefuna et al., 2005
- ⁴⁴ Balo et al., 2009
- ⁴⁵ Linden et al., 1999

Table 3

Adenosine receptor affinities of 8-cycloalkylxanthines

		K_i (nM) ^a			
		A ₁	A _{2A}	A _{2B}	A ₃
64	8-Cyclopentyl-theophylline	24 (r) ¹ 6.3 (r) ³ 26.1 (gp) ³ 6.4 (rb) ³ 2.9 (s) ³ 1.4 (c) ³	1,400 (r) ¹ 3,170 (r) ²⁷	710 (h) ² 902 (h) ²⁷	~100,000 (h) ¹ >10,000 (r) ²⁷
65	DPCPX (CPX)	3.0 (h) ⁴ 0.50 (r) ⁴ 1.0 (r) ⁵ 0.18 (r) ³ 1.06 (gp) ³ 3.9 (gp) ⁶ 0.21 (rb) ³ 0.10 (s) ³ 0.05 (c) ³ 0.29 (c) ⁶ 11.4 (d) ⁷	129 (h) ⁸ 60 (h) ⁹ 157 (r) ¹⁰ 500 (r) ⁵	51 (h) ⁴ 63.8 (h) ⁵ 186 (r) ⁵ 200 (r) ¹¹ 86.2 (m) ¹² 145 (gp) ¹¹ 96.0 (rb) ¹² 147 (d) ¹² 132 (d) ¹¹	795 (h) ¹³ 243 (h) ⁴ 509 (h) ⁷ 3,960 (h) ⁸ >10,000 (r) ⁹ 43,000 (r) ⁷ 708 (rb) ⁷ 115 (d) ⁷
66	2-Thio-CPX	0.655 (r) ¹⁴	314 (r) ¹⁴	2800 (h) ¹⁵	nd
67 KEM19 (rac.) BIIP-20 (S(-))	Apaxifylline (S(-)-configured enantiomer)	10.5 (mk) ^{16,b} 3 (r) ¹⁷	1,512 (mk) ^{16,b} 2,640 (r) ¹⁷	nd	nd
68 IRFI117	Midaxifylline (8-(1-Aminocyclo-pentyl)-1,3-dipropylX	26 ¹⁸	54,600 ¹⁸	nd	nd
69 KW3902 (NAX)	Rolofifylline 1,3-Dipropyl-8-(3-noradamantyl)X	0.72 (h) ¹⁹ 8.0 (h) ²⁰ 0.19 (r) ²¹ 12.6 (r) ¹⁹	108 (h) ¹⁹ 673 (h) ²⁰ 380 (r) ²¹ 510 (r) ¹⁹	296 (h) ²⁰	4,390 (h) ²⁰
70	1-Propyl-3-(S)-1-methylbenzyl-8-cyclopentylX	10.1 (r) ⁹	3,500 (r) ⁹	8,000 (h) ⁹	85 (h) ⁹ >10,000 (r) ⁹
71	1-Propyl-3-(R)-1-methylbenzyl-8-cyclopentylX	23.8 (r) ⁹	2,400 (r) ⁹	2,960 (h) ⁹	370 (h) ⁹
72	1-Propyl-3-benzyl-8-cyclopentylX	24.3 (h) ⁹ 8.70 (r) ⁹	511 (r) ⁹	8,000 (h) ⁹	54.6 (h) ⁹

		K_i (nM) ^a			
		A ₁	A _{2A}	A _{2B}	A ₃
73		7.1 (h) ⁹ 1.01 (r) ⁹	1,200 (h) ⁹ 492 (r) ⁹	625 (h) ⁹	395 (h) ⁹
74	PSB-16	5.74 (h) ⁹ 0.57 (r) ⁹	664 (r) ⁹	194 (h) ⁹	3,100 (h) ⁹
75		0.45 (r) ⁹	582 (r) ⁹	nd	1,190 (h) ⁹
77	PSB-36	0.7 (h) ⁹ 0.124 (r) ⁹	980 (h) ⁹ 552 (r) ⁹	187 (h) ⁹	2,300 (h) ⁹ 6,500 (r) ⁹
78		49 (h) ²² 55 (r) ²²	>10,000 (h) ²² >10,000 (r) ²²	nd	3,550 (h) ²²
79		29 (h) ²² 21 (r) ²²	>10,000 (h) ²² >10,000 (r) ²²	nd	>10,000 (h) ²²
80	BG-9719 (CVT-124)	0.45 (h) ¹⁹ 12 (h) ²¹ 0.67 (r) ¹⁹	1,100 (h) ¹⁹ 1,660 (h) ²¹ 1,250 (r) ¹⁹	611 (h) ²¹ 1,010 (m) ¹² 470 (rb) ¹² 742 (d) ¹²	4,810 (h) ²¹
81		18 (h) ²¹ 3.0 (r) ²¹	657 (h) ²¹ 264 (r) ²¹	802 (h) ²¹	>1,000 (h) ²¹
82	BG-9928	7.4 (h) ²⁰ 3.9 (mk) ²³ 1.3 (r) ²⁰ 29 (d) ²³	6,410 (h) ²⁰ 943 (mk) ²³ 2,440 (r) ²⁰ 4307 (d) ²³	90 (h) ²⁰	>10,000 (h) ²⁰
83		4.2 (r) ²⁴	>100 (r) ²⁴	nd	nd
84		0.99 (r) ²⁵ 3.0 (r) ²⁶ 3.0 (gp) ²⁵	430 (r) ²⁵	nd	nd

^ah = human; c = cow; d = dog; gp = guinea pig; m = mouse; mk = monkey; r = rat; rb = rabbit; a few data are from functional (cAMP) studies; nd = no data available A2B

^bdata for the racemate (KFM-19)

¹van Galen et al., 1994

²Bruns et al., 1986

- ³ Klotz et al., 1991
- ⁴ Bulicz et al., 2006
- ⁵ Kim et al., 2002
- ⁶ Ukena et al., 1986b
- ⁷ Auchampach et al., 1997
- ⁸ Klotz et al., 1998
- ⁹ Weyler et al., 2006
- ¹⁰ Müller et al., 2000
- ¹¹ Fozard et al., 2003
- ¹² Auchampach et al., 2009
- ¹³ Hayallah et al., 2002
- ¹⁴ Jacobson et al., 1989b
- ¹⁵ Jacobson et al., 1999
- ¹⁶ Schingnitz et al., 1991
- ¹⁷ Müller, 1997
- ¹⁸ Ceccarelli et al., 1995
- ¹⁹ Pfister et al., 1997
- ²⁰ Kiesman et al., 2006b
- ²¹ Kiesman et al., 2006a
- ²² Massip et al., 2006
- ²³ Doggrell, 2005
- ²⁴ Noguchi et al., 1997
- ²⁵ Suzuki et al., 1992a
- ²⁶ Shimada et al., 1992a

Table 4
Adenosine receptor affinities of 8-styrylxanthines and configurationally stable analogs

		K _i (nM) ^a			
		A ₁	A _{2A}	A _{2B}	A ₃
Styrylxanthines ^b					
85	1,3-Dipropyl-8-styrylX	22.2 (r) ¹	85.1 (r) ¹	nd	nd
86	1-Methyl-3-propyl-8-styrylX	31.1 (r) ¹	46.5 (r) ¹	nd	nd
87	Istradefylline (KW-6002) (K _i MAO-B = 28,000 nM) ²	841 (h) ^c 230 (r) ^c	12 (h) ³ 91.2 (h) ^c 2.2 (r) ⁴ 4.46 (r) ⁵	>10,000 (h) ^c	4,470 (h) ^c
88	8-Styrylcaffeine (K _i MAO-B = 2,864 nM) ⁶	3890 (r) ⁷	94 (r) ⁷	nd	nd
89	CSC (K _i MAO-B = 80.6 nM MAO-B) ⁵	28,000 (r) ⁷	54 (r) ⁷	8,200 ⁸	>10,000 (r) ⁹
90	KF17837	390 (r) ¹⁰	7.9 (r) ¹⁰ (E/Z) 1.0 (r) ¹⁰ (E)	1,500 (h) ¹⁰	nd
91	Styryl-DMPX	1,100 (r) ¹¹	27 (r) ¹¹	nd	nd
92	CS-DMPX	1,300 (r) ¹¹	13 (r) ¹¹	nd	nd
93	BS-DMPX	1,200 (r) ¹¹	8.2 (r) ¹¹ 10 (r) ¹²	>10,000 (h) ¹³	>10,000 (h) ¹³
94	<i>m</i> -Methoxystyryl-DMPX	1,280 (r) ¹³	12 (r) ¹³	nd	nd
95	<i>m</i> -Hydroxystyryl-DMPX	940 (r) ¹³	21 (r) ¹³	nd	nd
96	7-unsubst. analog of CS-DMPX	250 (r) ¹¹	410 (r) ¹¹	nd	nd
97	3-Propyl analog of CS-DMPX	102 (r) ¹¹	5.1 (r) ¹¹	nd	nd
98	<i>p</i> -SS-DMPX	4,900 (r) ¹²	240 (r) ¹²	nd	nd
99	MSX-2	900 (r) ¹⁴ 2,500 (h) ¹⁴	8.04 (r) ^{13,14} 5.38 (h) ^{14,d} 14.5 (h) ^{14,e}	>10,000 (h) ¹⁴ 2,900 (h) ¹⁵	>10,000 (h) ¹⁴
102	DMPTX (8-(3-thienylethenyl)-1,3-dipropylX)	561 (r) ¹⁶	19 (r) ¹⁶	nd	nd

		K _i (nM) ^a			
		A ₁	A _{2A}	A _{2B}	A ₃
103		44 (r) ⁷	>10,000 (r) ⁷	nd	nd
Analog of Styrylxanthines					
104	Phenylcyclopropyl-DMPX (<i>trans</i> , <i>rac</i> .)	4,600 (r) ⁸	1,700 (r) ⁸	nd	nd
105	β-Naphthyl-DMPX	980 (r) ⁸	380 (r) ⁸	nd	nd
106	3-Indolyl-DMPX	1,000 (r) ⁸	300 (r) ⁸	nd	nd
107	Phenylethynyl-DMPX	>3,000 (r) ⁸	314 (h) ^c 300 (r) ⁸	nd	5,000 (h) ^c
108	PhenylbutadienylX (K _i MAO-B = 42.1 nM) ⁵	nd	104 (r) ⁸	nd	nd

^ah = human; c = cow; d = dog; gp = guinea pig; m= mouse; mk = monkey; r = rat; rb = rabbit; a few A_{2B} data are from functional (cAMP) studies; nd = no data available

^b most data probably represent data from mixture of *E/Z* isomers since in dilute solutions light-induced isomerization occurs very fast and is difficult to avoid under standard testing conditions

^cMüller et al., unpublished data

^d recombinant receptors expressed in CHO cells

^e native receptors (post-mortem human brain cortex)

¹ Erickson et al., 1991

² Perzer et al. 2003

³ Kase, 2003

⁴ Shimada et al. 1997

⁵ Pretorius et al. 2008

⁶ Vlok et al. 2006

⁷ Jacobson et al., 1993a

⁸ Daly et al., 1995

⁹ van Galen et al., 1994

¹⁰ Nonaka et al., 1994a

- 11* Müller et al., 1997a
- 12* Müller et al. 1998b
- 13* Müller et al., 2000
- 14* Sauer et al. 2000
- 15* Solinas et al., 2005
- 16* Del Giudice et al., 1996
- 17* Massip et al., 2006
- 18* Müller et al., 1997a

Table 5

Adenosine receptor affinities of deazaxanthines and azaxanthines

		K_i (nM) ^a			
		A ₁	A _{2A}	A _{2B}	A ₃
Deazaxanthines					
109	9-Deaza-theophylline	5,400 (r) ^I	12,000 (r) ^I	nd	nd
110	9-Deazacaffeine	32,000 (r) ^I	72,000 (r) ^I	nd	nd
111	7-Deaza-theophylline	43,000 (r) ^I	>250,000 (r) ^I	nd	nd
112	1,3-Dimethyl-8-phenyl-9-deazaX	47 (r) ^I	510 (r) ^I	nd	nd
113	1,3-Dipropyl-8-phenyl-9-daX	13 (r) ^I	450 (r) ^I	nd	nd
114	1-Methyl-8-phenyl-9-deazaX	97 (r) ^I	2000 (r) ^I	520 (h) ²	2098 (h) ²
115	1-Propyl-8-phenyl-9-daX	45 (h) ² 39 (r) ^I	>10,000 (h) ² 1,200 (r) ^I	42 (h) ²	380 (h) ²
116	1,3-Dimethyl-8-phenyl-7-deazaX	3,100 ^I	12,000 ^I	nd	nd
117		14.8 (h) ³	64.6 (h) ³	3.02 (h) ³	>1,000 (h) ³
118		>1,000 (h) ⁴	10,000 (h) ⁴	11.0 (h) ⁴	>1,000 (h) ⁴
119		89.1 (h) ⁴	324 (h) ⁴	2.04 (h) ⁴	2,240 (h) ⁴
120		676 (h) ⁴	3,550 (h) ⁴	5.26 (h) ⁴	>1,000 (h) ⁴
121		183 (h) ⁵	nd	1 (h) ⁵	12,260 (h) ⁵
122	Tricyclic 9-DeazaX	346 (h) ⁶	164 (h) ⁶	nd	3.82 (h) ⁶
8-Azaxanthines					
123	1,3-Dimethyl-8-cyclopentyl-8-azaX	110,000 (c) ⁷	58,000 (c) ⁷	nd	nd
124	1,3-Dipropyl-8-cyclopentyl-8-azaX	1,300 (c) ⁷	13,000 (c) ⁷	nd	nd
125	1,3-Dimethyl-7-cyclopentyl-8-azaX	11,000 (c) ⁷	292,000 (c) ⁷	nd	nd
126	1,3-Dipropyl-7-cyclopentyl-8-azaX	340 (c) ⁷	10,000 (c) ⁷	nd	nd

^ah = human; c = cow; r = rat; a few A_{2B} data may be from functional (cAMP) studies; nd = no data available

- ¹ Grahner et al., 1994
- ² Hayallah et al., 2002
- ³ Carotti et al., 2006
- ⁴ Stefanachi et al., 2008
- ⁵ Esteve et al., 2006
- ⁶ Ishiyama et al., 2009
- ⁷ Franchetti et al., 1994

Table 6

Adenosine receptor affinities of tricyclic xanthine derivatives

		K _i (nM) ^a				
		A ₁	A _{2A}	A _{2B}	A ₃	
Imidazo[2,1- <i>i</i>]purin-5-ones						
127	KF20274	2.7 (r) ¹	290 (r) ¹	nd	nd	
128		22 (h) ² 6 (r) ²	4,400 (h) ² 2,700 (r) ²	580 (h) ²	>10,000 (h) ²	
129	PSB-10	1,700 (h) ³ 805 (r) ⁴	2,700 (h) ³ 6,040 (r) ⁴	nd	0.441 (h) ⁴	
130	PSB-11	1,640 (h) ³ 440 (r) ³	1,280 (h) ³ 2,100 (r) ³	2,100 (m) ⁴	2.34 (h) ³ K _D 4.9 (h) ⁵	
131	KF26777	1,800 (h) ⁶	470 (h) ⁶	620 (h) ⁶	0.20 (h) ⁶	
132		14,900 (r) ⁴	424 (r) ⁴	3,700 (m) ⁴	30,600 (h) ⁴	
Pyrimido[2,1- <i>f</i>]purinediones						
133		15,000 (r) ⁷	16,000 (r) ⁷	nd	nd	
134		20,000 (r) ⁷	>250,000 (r) ⁷	nd	nd	
135		>25,000 (r) ⁸	998 (r) ⁸	5,200 (h) ⁸	12,300 (h) ⁸	
136		26,800 (h) ⁹ 25,000 (r) ⁹	2,870 (h) ⁹ 219 (r) ⁹	ca. 10,000 (h) ⁹	>10,000 (h) ⁹	
137		16,700 (h) ⁹ >25,000 (r) ⁹	1,880 (h) ⁹ 147 (r) ⁹	ca. 10,000 (h) ⁹	>10,000 (h) ⁹	
138		>25,000 (r) ¹⁰	11,300 (h) ¹⁰ 699 (r) ¹⁰	nd	nd	
139		89 (r) ¹⁰	478 (r) ¹⁰	nd	1,290 (h) ¹⁰	
140		>10,000 (h) ¹¹ >25,000 (r) ¹¹	2,890 (h) ¹¹ 320 (r) ¹¹	ca. 10,000 (h) ¹¹	>10,000 (h) ¹¹	
141		>25,000 (h) ¹¹ ca. 25,000 (r) ¹¹	630 (h) ¹¹ 230 (r) ¹¹	7,200 (h) ¹¹	>10,000 (h) ¹¹	

		K_i (nM) ^a			
		A ₁	A _{2A}	A _{2B}	A ₃
142		>25,000 (h) ^{/1} ca. 25,000 (r) ^{/1}	4,560 (h) ^{/1} 330 (r) ^{/1}	ca. 10,000 (h) ^{/1}	>10,000 (h) ^{/1}
143		620(r) ^{/1}	860(r) ^{/1}	590 (h) ^{/1}	3,660 (h) ^{/1}
Pyridol[2,1- <i>f</i>]purinediones					
144		50 (h) ^{/2}	119 (h) ^{/2}	nd	4.0 (h) ^{/2}
145		>10,000 (h) ^{/2}	>10,000 (h) ^{/2}	nd	35 (h) ^{/2}
146		>1,000 (h) ^{/3}	242 (h) ^{/3}	nd	4.2 (h) ^{/3}
147		>1,000 (h) ^{/3}	>1,000 (h) ^{/3}	>1,000 (h) ^{/3}	2.24 (h) ^{/3}
Imidazo-, Pyrrolo- and Triazolopurinediones					
148		>1,000 (h) ^{/4}	>1,000 (h) ^{/4}	>1,000 (h) ^{/4}	0.8 (h) ^{/4}
149		>1,000 (h) ^{/4}	>1,000 (h) ^{/4}	>1,000 (h) ^{/4}	3.5 (h) ^{/4}
150		>10,000 (h) ^{/5}	2,050 (h) ^{/5}	>100,000 (h) ^{/5}	1,330 (h) ^{/5}
4,5-Dihydro-6H,8H-pyrimido[1,2,3- <i>cd</i>]purine-8,10-diones					
151		1,440 (r) ^{/6}	12,400 (r) ^{/6}	42,600 (h) ^{/6}	nd
152	PSB-63	16.9 (r) ^{/6} 90.6 (h) ^{/6}	22,000 (r) ^{/6} 34,500 (h) ^{/6}	3,190 (h) ^{/6}	>10,000 (h) ^{/6}
153		40.6 (r) ^{/6} 13.8 (h) ^{/6}	23,400 (r) ^{/6} ca. 25,000 (h) ^{/6}	22,300 (h) ^{/6}	188 (h) ^{/6}
Oxazolol[3,2- <i>a</i>]purinone					
154		770 (r) ^{/7}	20,600 (r) ^{/7}	nd	nd

^a_h = human; m = mouse; r = rat; a few A_{2B} data may be from functional (cAMP) studies; nd = no data available

¹ Suzuki et al., 1992b

² Vu et al., 2006

³ Ozola et al., 2003

⁴ Müller et al., 2002a

- ⁵ Müller et al., 2002b
- ⁶ Saki et al., 2002
- ⁷ Geis et al. 1995
- ⁸ Drabczynska et al., 2004
- ⁹ Drabczynska et al., 2006
- ¹⁰ Drabczynska et al., 2007a
- ¹¹ Drabczynska et al., 2007b
- ¹² Priego et al., 2002
- ¹³ Priego et al., 2008
- ¹⁴ Baraldi et al., 2005
- ¹⁵ Pastorin et al., 2005
- ¹⁶ Weyler et al., 2006
- ¹⁷ Müller, 1994

Table 7
Adenosine receptor affinities of functionalized xanthenes as molecular probes

		K _i (nM) ^a				
		A ₁	A _{2A}	A _{2B}	A ₃	
Spin-labeled probes						
155		5.47 (r) ^I	8,780 (r) ^I	>1,000 (h) ^I	1,700 (h) ^I	
156		8.23 (r) ^I	3,800 (r) ^I	3,100 (h) ^I	ca. 10,000 (h) ^I	
157		15.7 (r) ^I	1,270 (r) ^I	48 (h) ^I	350 (h) ^I	
167	TEMPO-XAC	4.9 (r) ² 0.30 (c) ²	nd	nd	nd	
Irreversible ligands						
158	FSCPX ^{3,4}	10 (r) ³	nd	nd	nd	
160	ISC	42,600 (r) ⁵ 51,400 (gp) ⁵ 89,500 (rb) ⁵ 63,400 (c) ⁵	146 (r) ⁵ 160 (gp) ⁵ 413 (rb) ⁵ 516 (c) ⁵	nd	nd	
164	m-DITC-XAC	2.39 (r) ⁶ 52 (r) ⁷	nd	nd	nd	
165	p-DITC-XAC	6.60 (r) ⁶ 27 (r) ⁷	nd	nd	nd	
Radioligands						
159	[¹⁸ F]CPPX	1.26 (h) ⁸ 0.63 (r) ⁸ 1.37(p) ⁸ 0.18 (c) ⁸	940 (h) ⁸ 812 (r) ⁸	nd	nd	
166		40 [IC ₅₀] (c) ⁹	nd	nd	nd	
172	[¹²⁵ I]PAPA-XAC	0.1 (c) ¹⁰	nd	nd	nd	
Biotin conjugates						
161		54 (r)/1,12	nd	nd	nd	
162		50 (r)/1,12	nd	nd	nd	

		K_i (nM) ^a			
		A ₁	A _{2A}	A _{2B}	A ₃
163		60 (r)/2	nd	nd	nd
Various conjugates					
168	D-Lys-XAC	1.74 [IC ₅₀] (r) 13	159 [IC ₅₀] (r) 13	nd	nd
169		35 (r)/2	nd	nd	nd
170		8.1 (r) ² 0.8 (c) ²	nd	nd	nd
171	DTPA-XAC	59.5 (r) ² 3.25 (c) ²	nd	nd	nd
Fluorescent ligands					
173	FITC-XAC	125 (r) ² 9.3 (c) ²	nd	nd	nd
174	XAC-BY630	151 (h)/4	nd	nd	nd
Bivalent ligand conjugates					
175 ^{11,15}		31 (r)	nd	nd	nd
176	A _{2A} antagonist/D ₂ agonist for A _{2A} /D ₂ receptor heteromers K _i D ₂ (s) = 1.0 nM) ¹⁶	nd	55 (s)/6	nd	nd

^a h = human; c = cow; d = dog; gp = guinea pig; p = pig; r = rat; rb = rabbit; s = sheep

¹ Ilas et al., 2005

² Jacobson et al., 1987b

³ Scammels et al., 1994

⁴ Muijwijk-Koezen et al., 2001

⁵ Ji et al., 1993

⁶ Jacobson et al., 1989a

⁷ Stiles and Jacobson, 1988

⁸ Holschbach et al., 2002

- ⁹ Jacobson et al., 1992b
- ¹⁰ Stiles and Jacobson, 1987
- ¹¹ Jacobson, 2009
- ¹² Jacobson et al., 1987c
- ¹³ Jacobson et al., 1986b
- ¹⁴ Briddon et al. 2004
- ¹⁵ Jacobson et al., unpublished
- ¹⁶ Soriano et al., 2009